

Synthesis and Biophysical Properties of C5-Functionalized LNA (Locked Nucleic Acid)

Pawan Kumar,^{†,‡} Michael E. Østergaard,[†] Bharat Baral,[†] Brooke A. Anderson,[†] Dale C. Guenther,[†] Mamta Kaura,[†] Daniel J. Raible,[†] Pawan K. Sharma,[‡] and Patrick J. Hrdlicka^{*,†}


[†]Department of Chemistry, University of Idaho, Moscow, Idaho 83844-2343, United States

[‡]Department of Chemistry, Kurukshetra University, Kurukshetra 136119, India

S Supporting Information

ABSTRACT: Oligonucleotides modified with conformationally restricted nucleotides such as locked nucleic acid (LNA) monomers are used extensively in molecular biology and medicinal chemistry to modulate gene expression at the RNA level. Major efforts have been devoted to the design of LNA derivatives that induce even higher binding affinity and specificity, greater enzymatic stability, and more desirable pharmacokinetic profiles. Most of this work has focused on modifications of LNA's oxymethylene bridge. Here, we

describe an alternative approach for modulation of the properties of LNA: i.e., through functionalization of LNA nucleobases. Twelve structurally diverse C5-functionalized LNA uridine (U) phosphoramidites were synthesized and incorporated into oligodeoxyribonucleotides (ONs), which were then characterized with respect to thermal denaturation, enzymatic stability, and fluorescence properties. ONs modified with monomers that are conjugated to small alkynes display significantly improved target affinity, binding specificity, and protection against 3'-exonucleases relative to regular LNA. In contrast, ONs modified with monomers that are conjugated to bulky hydrophobic alkynes display lower target affinity yet much greater 3'-exonuclease resistance. ONs modified with C5-fluorophore-functionalized LNA-U monomers enable fluorescent discrimination of targets with single nucleotide polymorphisms (SNPs). In concert, these properties render C5-functionalized LNA as a promising class of building blocks for RNA-targeting applications and nucleic acid diagnostics.



INTRODUCTION

The development of novel conformationally restricted nucleotides is a vibrant area of research.^{1,2} Efforts are driven by the interesting properties of oligodeoxyribonucleotides (ONs) modified with classic examples of conformationally restricted nucleotides such as homo-DNA,³ hexitol nucleic acid (HNA),⁴ cyclohexane nucleic acid (CeNA),⁵ bicyclo DNA,⁶ tricyclo DNA,⁷ or locked nucleic acid (LNA),^{8,9} which is also known as bridged nucleic acid (BNA).¹⁰ ONs comprising these building blocks display high affinity toward complementary DNA/RNA often due to reduced entropic binding penalties¹¹ and are accordingly in high demand for a wide range of nucleic acid targeting applications in molecular biology, biotechnology, and pharmaceutical science.¹² Their use as RNA-targeting antisense oligonucleotides to decrease gene expression is a particularly prominent example.^{12b}

LNA is an especially interesting member of this compound class because it induces some of the greatest duplex stabilizations observed to date (Figure 1).^{8–10} Modulation of gene expression through LNA-mediated targeting of mRNA, pre-mRNA, or miRNA has accelerated gene function studies and led to the development of LNA-based drug candidates against diseases of genetic origin.^{13,14} Other applications of LNA include its use as an in situ hybridization probe to monitor spatiotemporal expression patterns of miRNAs.¹⁵

Many analogues of LNA have been synthesized with the aim of further improving the binding affinity/specificity, enzymatic stability and pharmacokinetic characteristics of LNA.^{1,2,16} The vast majority of these efforts have focused on modifying the oxymethylene bridge spanning the C2'/C4'-positions and/or introducing minor-groove-oriented substituents on the bridge. These structural perturbations have resulted in improved enzymatic stability and altered biodistribution and/or toxicity profiles but have generally not resulted in major improvements in binding affinity and specificity.

C5-functionalized pyrimidine DNA monomers have also attracted considerable attention,^{17,18} as they enable predictable positioning of functional entities in the major groove of nucleic acid duplexes.¹⁹ Small C5-alkynyl substituents such as propyn-1-yl and 3-aminopropyn-1-yl induce considerable duplex thermostabilization relative to unmodified duplexes, while large hydrophobic substituents typically decrease duplex thermostability. Attachment of polarity-sensitive fluorophores to the C5 position of DNA pyrimidine monomers has produced several interesting oligonucleotide probes for structural studies of nucleic acids and applications in nucleic acid diagnostics.^{12c,20}

Received: March 15, 2014

Published: May 5, 2014





Figure 1. Structure of LNA-T and C5-functionalized analogues thereof studied herein.

Scheme 1. Synthesis of C5-Alkynyl-Functionalized LNA Uridine Phosphoramidites^a



^aAbbreviations: CAN, ceric ammonium nitrate; DMTrCl, 4,4'-dimethoxytrityl chloride; PCl, 2-cyanoethyl-*N,N*-diisopropylchlorophosphoramidite; DIPEA, *N,N*-diisopropylethylamine.

In light of the above and our ongoing interest in LNA chemistry,^{12c,21} we recently set out to study C5-alkynyl-functionalized LNA uridine (U) monomers, on the basis of the hypothesis that these monomers will exhibit beneficial properties from both compound classes, i.e., high affinity toward RNA complements and good mismatch discrimination (LNA), along with the ability to position blocking groups in the major groove to confer protection against enzymatic degradation (C5 substituent). The results from our preliminary studies have been very encouraging.²² ONs modified with small C5-alkynyl-functionalized LNA-U monomers display high affinity

toward complementary RNA and moderate protection against 3'-exonucleases, while ONs modified with large C5-alkynyl-functionalized LNA-U monomers display greatly increased enzymatic stability but decreased RNA affinity.

In the present article, we describe full experimental details concerning the synthesis of 12 different C5-functionalized LNA-U phosphoramidites, their incorporation into ONs, and the characterization of these modified ONs by means of thermal denaturation experiments, analysis of thermodynamic parameters, nuclease stability experiments, and fluorescence spectroscopy. The monomers in question were selected to


ensure a representation of substituents with different sizes, polarities, linker chemistries, and fluorescence characteristics (Figure 1).

RESULTS AND DISCUSSION

Synthesis of Phosphoramidites. Our route to target phosphoramidites **5b–l** initiates from LNA uridine diol **1**, which is obtained from commercially available diacetone- α -D-allose in ~52% yield (Scheme 1).²³ C5-iodination of **1** was accomplished through treatment with iodine and ceric ammonium nitrate (CAN) in acetic acid at 80 °C for ~40 min to afford nucleoside **2** in 87% yield. Prolonged heating and/or higher reaction temperatures result in the formation of nonpolar impurities, which complicate purification and reduce product yield. Subsequent O5'-dimethoxytritylation using standard conditions afforded the key intermediate **3** in 84% yield. Terminal alkynes²⁴ were then coupled with **3** under typical Sonogashira conditions²⁵ to provide C5-alkynyl-functionalized LNA uridines **4a–j** in 53–87% yield. Careful deoxygenation is critical to the outcome of these reactions, as they otherwise do not proceed to completion. Finally, O3'-phosphitylation using 2-cyanoethyl-*N,N'*-diisopropylchlorophosphoramidite afforded target phosphoramidites **5b–j** in 43–83% yield.

In order to obtain C5-triazolyl-functionalized LNA uridine phosphoramidites **5k** and **5l**, C5-ethynyl-functionalized LNA uridine **4b** (obtained via standard TBAF-mediated desilylation of **4a**) was reacted with 1-azidopyrene²⁶ or 1-azidomethylpyrene²⁷ in a Cu(I)-catalyzed azide alkyne Huisgen 1,3-dipolar cycloaddition,²⁸ followed by standard O3'-phosphitylation (Scheme 2).

Scheme 2. Synthesis of C5-Triazolyl-Functionalized LNA Uridine Phosphoramidites



ON Synthesis. Phosphoramidites **5b–l** were used in machine-assisted solid-phase DNA synthesis (0.2 μmol scale) to incorporate monomers **K–Z** into ONs. Standard conditions were used except for extended hand-coupling (generally 15 min with 4,5-dicyanoimidazole or 5-[3,5-bis(trifluoromethyl)phenyl]-1*H*-tetrazole as activator) when using **5b–l**, which typically resulted in stepwise coupling yields of >95%. The composition and purity of all modified ONs was ascertained by MALDI MS analysis (Table S1, Supporting Information) and ion-pair reversed-phase HPLC, respectively. ONs containing a

single incorporation in the 5'-GTGABATGC context are denoted **K1–M1** and so on. Similar conventions apply for ONs in the **B2–B4** series (Table 1). Reference DNA and RNA strands are denoted **D1/D2** and **R1/R2**, respectively.

Thermal Denaturation Experiments: Binding Affinity.

The thermostabilities of duplexes between modified ONs and complementary DNA/RNA were evaluated by determining their thermal denaturation temperature (T_m) in medium salt phosphate buffer ($[\text{Na}^+] = 110 \text{ mM}$, pH 7.0). T_m 's of modified duplexes are discussed relative to T_m 's of unmodified reference duplexes (Table 1).

As anticipated, ONs modified with one or two conventional LNA-T monomers form very thermostable duplexes with RNA targets in particular (see ΔT_m values for **L1–L4**, Table 1). Interestingly, ONs modified with LNA monomers featuring small C5-alkynyl moieties generally result in the formation of even more thermostable duplexes (compare ΔT_m values of **K/M/N** series with those of the **L** series, Table 1). The effect is most pronounced for ONs modified with aminopropynyl-functionalized monomer **N**, which display increases in T_m values of up to +13 °C per modification. The greater thermostability of duplexes modified with **K/M/N** monomers is most likely the result of enhanced stacking interactions^{18a} and, in the case of monomer **N**, favorable electrostatic interactions and/or hydration in the major groove, in a manner similar to that previously suggested for C5-aminopropynyl-modified DNA.^{18e,h}

In contrast, duplexes modified with LNA monomers that are conjugated to medium-sized hydrophobic C5-alkynyl substituents are less thermostable than the corresponding LNA-modified duplexes (compare ΔT_m values of the **O/P**-series with those of the **L** series, Table 1). The trend is particularly prominent in DNA:RNA duplexes, presumably due to a suboptimal fit of the C5-alkynyl substituent in the narrow major groove of *A/B*-type duplexes. However, other factors, such as different influences on hydration,^{18c} cannot be ruled out. The resulting duplexes are, nevertheless, still significantly more stable than the unmodified reference duplexes.

ONs modified with LNA monomers that are conjugated to long hydrophobic C5-alkynyl substituents display even lower affinity toward their targets (see ΔT_m values of the **Q/S** series, Table 1). It is particularly noteworthy that duplexes involving the doubly modified **Q4** or **S4** do not display transitions above 10 °C. Similar observations have been made with doubly cholesterol-modified 2'-amino-LNA.²⁹ We hypothesize that interactions between the hydrophobic groups in single-stranded **Q4** or **S4** interfere with duplex formation. The fact that DNA duplexes with interstrand zipper arrangements of two **Q** monomers are rather thermostable supports this hypothesis (see Table S2, Supporting Information).

Similarly, ONs modified with LNA monomers that are conjugated to large hydrophobic fluorophores generally form very thermolabile duplexes, regardless of whether the fluorophore is attached via an alkynyl or triazolyl linker (see ΔT_m values of the **V–Z** series, Table 1). The use of monomers in which the fluorophore is attached to the nucleobase via a short rigid linker, such as in monomers **W–Y**, results in particularly unstable duplexes. Once again, we speculate that these trends reflect a poor fit of the fluorophore in the major groove; short rigid linkers between the fluorophore and nucleobase moieties may prevent the fluorophore from sampling more suitable conformational space. Interestingly, with the exception of pyrene- and perylene-functionalized **W4**

Table 1. ΔT_m Values of Duplexes between ONs Modified with C5-Functionalized LNA Monomers and Complementary DNA/RNA Measured Relative to Unmodified Duplexes^a

ON	duplex	$\Delta T_m/\text{mod}$ (°C)													
		B =	L	K	M	N	O	P	Q	S	V	W	X	Y	Z
B1	5'-GTG <u>ABA</u> TGC	+5.0	+7.0	+7.0	+8.0	+4.5	+4.0	+1.0	-5.5	-6.5	-8.5	-12.5	-10.5	-5.5	
D2	3'-CAC TAT ACG														
D1	5'-GTG ATA TGC	+4.0	+5.5	+5.5	+6.5	+3.0	+1.0	+0.5	-5.0	-7.5	-9.5	-12.0	-13.5	-6.5	
B2	3'-CAC <u>BAT</u> ACG														
D1	5'-GTG ATA TGC	+6.5	+5.5	+7.0	+9.5	+4.5	+3.5	+1.0	-3.5	-4.0	-10.5	-11.5	-12.5	-5.5	
B3	3'-CAC <u>TAB</u> ACG														
D1	5'-GTG ATA TGC	+5.5	+5.5	+5.5	+8.0	nd	+3.0	<-10.0	<-10.0	+0.5	-6.5	<-10.0	-4.0	-2.0	
B4	3'-CAC <u>BAB</u> ACG														
B1	5'-GTG <u>ABA</u> TGC	+9.5	+11.0	+9.5	+13.0	+6.0	+5.5	+4.0	-2.0	-4.0	-2.0	-12.0	-2.0	-1.5	
R2	3'-CAC UAU ACG														
R1	5'-GUG AUA UGC	+6.5	+8.5	+8.0	+10.0	-0.5	+2.0	+3.5	±0	-6.0	-1.5	-12.0	-10.0	-5.0	
B2	3'-CAC <u>BAT</u> ACG														
R1	5'-GUG AUA UGC	+9.5	+8.5	+10.0	+12.5	+2.5	+2.0	+2.5	-1.0	±0	-5.5	-11.0	-9.0	-1.0	
B3	3'-CAC <u>TAB</u> ACG														
R1	5'-GUG AUA UGC	+8.0	+8.5	+8.0	+11.0	nd	+4.5	<-8.5	<-8.5	+2.0	-5.5	<-8.5	-2.0	-0.5	
B4	3'-CAC <u>BAB</u> ACG														

^a ΔT_m = change in T_m values relative to unmodified reference duplexes **D1:D2** ($T_m \equiv 29.5$ °C), **D1:R2** ($T_m \equiv 27.0$ °C), and **D2:R1** ($T_m \equiv 27.0$ °C); T_m values were determined as the first-derivative maximum of denaturation curves (A_{260} vs T) recorded in medium salt phosphate buffer ($[\text{Na}^+] = 110$ mM, $[\text{Cl}^-] = 100$ mM, pH 7.0 ($\text{NaH}_2\text{PO}_4/\text{Na}_2\text{HPO}_4$)), using 1.0 μM of each strand. T_m values are averages of at least two measurements within 1.0 °C; see Figure 1 for structures of monomers. nd = not determined. Data for duplexes between L/K/N/Q/S-modified ONs and complementary RNA has been previously reported in ref 22.

and **X4**, duplexes entailing the doubly modified **B4** ONs are considerably more stable than those entailing their singly modified counterparts (e.g., compare $\Delta T_m/\text{mod}$ of **B4:D1** relative to **B2:D1** and **B3:D1**, Table 1). Similar stabilizing trends have been reported for other densely fluorophore modified duplexes and were attributed to the formation of chromophore arrays in the major groove.¹⁹ The presence of pyrene excimer signals in the steady-state fluorescence emission spectra of duplexes between **V4/Y4/Z4** and DNA/RNA complements supports this hypothesis (Figure S3, Supporting Information).

Thermodynamic Analysis of Duplexes Modified with C5-Functionalized LNA-U Monomers. The T_m -based conclusions are largely corroborated through analysis of the thermodynamic parameters for duplex formation, which were derived from thermal denaturation curves through curve fitting.³⁰ Thus, the formation of duplexes between conventional LNA **L1–L3** and complementary DNA or RNA is 4–7 and 8–13 kJ/mol more favorable, respectively, in comparison to unmodified reference duplexes (see $\Delta\Delta G^{298}$ values for **L1–L3**, Table 2). The greater stability of LNA-modified duplexes is generally a result of lower enthalpy ($\Delta\Delta H < 0$ kJ/mol for **L2** and **L3**, Table 2), but entropic stabilization is also observed ($\Delta(T^{298}\Delta S) < 0$ kJ/mol for **L1**, Table 2).

Formation of duplexes entailing ONs modified with **K/M/N** monomers, which are conjugated to small and/or relatively polar alkynes, is 1–7 kJ/mol more favorable than formation of the corresponding LNA-modified duplexes (compare $\Delta\Delta G^{298}$ values for the **K/M/N** series vs **L** series, Table 2). The additional duplex stabilization is generally enthalpic in origin,

which is consistent with improved base stacking due to the extended π surface of the C5-alkynyl-functionalized LNA monomers (compare $\Delta\Delta H$ values for the **K/M/N** series vs **L** series, Table 2); similar trends have been previously reported for C5-propynyl-functionalized DNA monomers.³¹

Duplexes involving ONs modified with monomers **O/P/Q**, which are conjugated to moderately large hydrophobic alkynyl substituents, are 0–7 kJ/mol less favorable than the corresponding LNA-modified duplexes (compare $\Delta\Delta G^{298}$ values for the **O/P/Q** series vs the **L** series, Table 2). Comparison with **K**-modified duplexes suggests that the hydrophobic substituents counteract the favorable enthalpy of the extended π surfaces (compare $\Delta\Delta H$ values for the **O/P/Q** series vs the **K** series, Table 2). One possible interpretation of this is that the hydrophobic substituents disrupt hydration in the major groove.

DNA duplexes modified with C5-cholesterol-functionalized LNA monomer **S** are less stable than the control duplex, whereas duplexes with RNA are slightly more stable (see $\Delta\Delta G^{298}$ values for **S1–S3**, Table 2). The favorable enthalpic contribution of the alkyne functionality is fully counteracted by low entropy in DNA duplexes but only partially counteracted in DNA:RNA duplexes (compare $\Delta\Delta H$ vs $\Delta(T^{298}\Delta S)$ for **S1–S3**, Table 2).

Thermal Denaturation Studies: Binding Specificity. The binding specificities of centrally modified ONs (**B1** series) were determined by using DNA/RNA targets with mismatched nucleotides opposite of the modified monomer. As expected,^{8–10} LNA-modified ON **L1** displays improved binding specificity relative to unmodified reference strand **D1**, as

Table 2. Thermodynamic Parameters for Formation of Duplexes Modified with C5-Functionalized LNA Monomers^a

ON	sequence	+complementary DNA			+complementary RNA		
		ΔG^{298} [$\Delta\Delta G^{298}$] (kJ/mol)	ΔH [$\Delta\Delta H$] (kJ/mol)	$-T^{298}\Delta S$ [$\Delta(T^{298}\Delta S)$] (kJ/mol)	ΔG^{298} [$\Delta\Delta G^{298}$] (kJ/mol)	ΔH [$\Delta\Delta H$] (kJ/mol)	$-T^{298}\Delta S$ [$\Delta(T^{298}\Delta S)$] (kJ/mol)
D1	5'-GTG ATA TGC	-42	-314	271	-36	-278	241
D2	3'-CAC TAT ACG	-42	-314	271	-39	-293	254
L1	5'-GTG <u>ALA</u> TGC	-47 [-5]	-297 [+17]	250 [-21]	-49 [-13]	-309 [-31]	260 [+19]
L2	3'-CAC <u>LAT</u> ACG	-46 [-4]	-332 [-18]	286 [+15]	-47 [-8]	-331 [-38]	283 [+29]
L3	3'-CAC <u>TAL</u> ACG	-49 [-7]	-332 [-18]	283 [+12]	-50 [-11]	-340 [-47]	290 [+36]
K1	5'-GTG <u>AKA</u> TGC	-49 [-7]	-350 [-36]	301 [+30]	-53 [-17]	-424 [-146]	371 [+130]
K2	3'-CAC <u>KAT</u> ACG	-49 [-7]	-349 [-35]	300 [+29]	-49 [-10]	-367 [-74]	317 [+63]
K3	3'-CAC <u>TAK</u> ACG	-52 [-10]	-372 [-58]	319 [+48]	-57 [-18]	-414 [-121]	357 [+103]
M1	5'-GTG <u>AMA</u> TGC	-51 [-9]	-390 [-76]	339 [+68]	-52 [-16]	-386 [-108]	334 [+93]
M2	3'-CAC <u>MAT</u> ACG	-50 [-8]	-394 [-80]	344 [+73]	-51 [-12]	-398 [-105]	347 [+93]
M3	3'-CAC <u>TAM</u> ACG	-51 [-9]	-360 [-46]	309 [+38]	-51 [-12]	-367 [-74]	316 [+62]
N1	5'-GTG <u>ANA</u> TGC	-51 [-9]	-353 [-39]	302 [+31]	-51 [-15]	-324 [-46]	272 [+31]
N2	3'-CAC <u>NAT</u> ACG	-49 [-7]	-362 [-48]	313 [+42]	-52 [-13]	-364 [-71]	312 [+58]
N3	3'-CAC <u>TAN</u> ACG	-52 [-10]	-361 [-47]	309 [+38]	-52 [-13]	-325 [-32]	272 [+18]
O1	5'-GTG <u>AQA</u> TGC	-47 [-5]	-337 [-23]	290 [+19]	-46 [-10]	-337 [-59]	291 [+50]
O2	3'-CAC <u>OAT</u> ACG	-44 [-2]	-322 [-8]	278 [+7]	-43 [-4]	-366 [-73]	322 [+68]
O3	3'-CAC <u>TAQ</u> ACG	-46 [-4]	-324 [-10]	278 [+7]	-44 [-5]	-340 [-47]	296 [+42]
P1	5'-GTG <u>APA</u> TGC	-45 [-3]	-334 [-20]	289 [+18]	-45 [-9]	-327 [-49]	282 [+41]
P2	3'-CAC <u>PAT</u> ACG	-43 [-1]	-324 [-10]	281 [+10]	-43 [-4]	-351 [-58]	308 [+54]
P3	3'-CAC <u>TAP</u> ACG	-44 [-2]	-339 [-25]	294 [+23]	-43 [-4]	-365 [-72]	321 [+67]
Q1	5'-GTG <u>AQA</u> TGC	-45 [-3]	-346 [-32]	301 [+30]	-45 [-9]	-347 [-69]	302 [+61]
Q2	3'-CAC <u>QAT</u> ACG	-45 [-3]	-411 [-97]	371 [+100]	-46 [-7]	-377 [-84]	331 [+77]
Q3	3'-CAC <u>TAQ</u> ACG	-43 [-1]	-287 [+27]	243 [-28]	-43 [-4]	-360 [-67]	317 [+63]
S1	5'-GTG <u>ASA</u> TGC	-37 [+5]	-317 [-3]	280 [+9]	-39 [-3]	-333 [-55]	294 [+53]
S2	3'-CAC <u>SAT</u> ACG	-39 [+3]	-380 [-66]	342 [+71]	-42 [-3]	-359 [-66]	316 [+62]
S3	3'-CAC <u>TAS</u> ACG	-40 [+2]	-380 [-66]	339 [+68]	-40 [-1]	-355 [-62]	315 [+61]

^aParameters were determined from thermal denaturation curves, which were recorded as described in Table 1. $\Delta\Delta G^{298}$, $\Delta\Delta H$, and $\Delta(T^{298}\Delta S)$ are calculated relative to reference duplexes D1:D2, D1:R2, and D2:R1.

evidenced by the more pronounced decreases in T_m values of mismatched duplexes (compare ΔT_m values for L1 and D1, Table 3). Interestingly, many of the C5-functionalized LNA monomers induce additional improvements in binding specificity (note ΔT_m values of K1/M1/N1/O1/P1/Q1, Table 3). It is recognized that nucleotide modifications, which improve target affinity as well as binding specificity, are desirable for nucleic acid targeting applications.³² Cholesterol-functionalized LNA S1 and fluorophore-functionalized LNAs V1/W1/X1/Y1/Z1 display poor discrimination of mismatched DNA targets but maintain reasonable specificity against RNA targets (Table 3). These trends are indicative of different binding modes of the pyrene and perylene moieties in DNA:DNA vs DNA:RNA duplexes. Intercalation of aromatic units, which is known to stabilize mismatched base pairs,³³ is more favorable in DNA:DNA than in DNA:RNA duplexes.³⁴ For a discussion of the binding specificities of double-modified ONs (B4-series), see the Supporting Information (Table S3).

3'-Exonuclease Stability of C5-Functionalized LNA. Next, we examined the enzymatic stability of select C5-functionalized LNAs and reference strands in the presence of

snake venom phosphodiesterase (SVPDE), a 3'-exonuclease. As expected, unmodified D2 is quickly degraded (>95% cleavage after 15 min), while the singly modified LNA L2 offers moderate protection against SVPDE (>95% cleaved after 50 min) (Figure 2). ONs modified with a single C5-ethynyl- or C5-aminopropynyl-functionalized LNA monomer are markedly more resistant toward SVPDE degradation (~55% and 35% cleavage of K2 and N2, respectively, after 2 h). Interestingly, ONs that are modified with LNA monomers conjugated to large hydrophobic substituents are completely inert against SVPDE-mediated degradation, following a brief period of cleavage (see degradation profiles for Q2 and S2; Figure 2). M2/O2/P2 also display markedly increased 3'-exonuclease resistance (Figure S1, Supporting Information). As expected, these trends are even more pronounced with the doubly modified B4 series (Figure 2). Thus, the data strongly suggest that large hydrophobic C5-alkynyl substituents offer effective protection from enzymatic degradation.

Fluorescence Properties of C5-Functionalized LNA. Steady-state fluorescence emission spectra of ONs modified with C5-fluorophore-functionalized LNA monomers and the

Table 3. Discrimination of Mismatched DNA/RNA Targets by Singly Modified LNAs and Reference ONs^a

ON	sequence	DNA: 3'-CAC <u>B</u> AT ACG				RNA: 3'-CAC <u>U</u> BU ACG			
		T_m		ΔT_m		T_m		ΔT_m	
		A	C	G	T	A	C	G	U
D1	5'-GTG ATA TGC	29.5	-16.5	-8.0	-15.5	27.0	<-17.0	-4.5	<-17.0
L1	5'-GTG ALA TGC	34.5	-18.0	-11.0	-16.0	36.5	-19.0	-8.0	-18.5
K1	5'-GTG AKA TGC	36.5	-20.0	-15.5	-18.5	38.0	-20.5	-13.5	-22.0
M1	5'-GTG AMA TGC	36.5	-20.0	-11.5	-18.5	36.5	-18.5	-9.5	-20.0
N1	5'-GTG ANA TGC	37.5	-19.0	-12.0	-17.5	40.0	-18.5	-11.5	-22.5
O1	5'-GTG AOA TGC	34.0	-20.5	-16.5	-18.0	33.0	-20.0	-9.5	-20.0
P1	5'-GTG APA TGC	33.5	-21.5	-17.0	-20.5	32.5	-20.5	-11.5	-19.5
Q1	5'-GTG AQA TGC	30.5	-18.0	-13.0	-16.5	31.0	-19.5	-10.0	-20.0
S1	5'-GTG ASA TGC	24.0	-11.5	-10.0	-11.0	25.0	-15.0	-9.0	<-15.0
V1	5'-GTG AVA TGC	23.0	-7.5	-10.0	-7.5	23.0	<-13.0	-10.5	<-13.0
W1	5'-GTG AWA TGC	21.0	+6.0	-7.0	+3.0	25.0	<-15.0	<-15.0	<-15.0
X1	5'-GTG AXA TGC	17.0	+4.5	± 0.0	+3.5	15.0	<-5.0	<-5.0	<-5.0
Y1	5'-GTG AYA TGC	19.0	-1.0	-4.0	-2.5	25.0	<-15.0	-8.0	<-15.0
Z1	5'-GTG AZA TGC	24.0	-10.0	<-14.0	-9.5	25.5	-1.5	<-15.5	<-15.5

^aFor experimental conditions and sequences, see Table 1. ΔT_m = change in T_m value relative to fully matched ON:DNA or ON:RNA duplex (B = A). Data for L1/K1/N1/Q1/S1 against mismatched RNA have been previously published in ref 22.




Figure 2. 3'-Exonuclease (SVPDE) degradation of singly (left, 3'-CAC BAT ACG) and doubly modified (right, 3'-CAC BAB ACG) C5-functionalized LNA and reference strands. Nuclease degradation studies were performed in magnesium buffer (50 mM Tris-HCl, 10 mM Mg²⁺, pH 9.0) by using 3.3 μ M ONs and 0.03 U of SVPDE. Data depicted in the left panel have been previously reported in ref 22.

corresponding duplexes with complementary or mismatched DNA targets were recorded to gain further insight into the binding modes of the fluorophores. In addition to studying the fluorescence properties of B1 and B4 probes in the presence or absence of matched/mismatched DNA/RNA (Figures S2 and S3, Supporting Information), we also studied centrally modified 13-mer ONs (V5–Z5 series) and their duplexes with matched/mismatched DNA targets (Figure 3). The thermal denaturation characteristics of these ONs (Table S4, Supporting Information) closely follow those of the singly modified 9-mer ONs: i.e. (i) the corresponding duplexes with DNA/RNA targets are less stable than unmodified reference duplexes (only Z5-modified duplexes are slightly more stable) and (ii) W5–Y5 display very poor thermal discrimination of mismatched DNA targets, while V5 and Z5 display similar binding specificity as the unmodified reference strands.

V/Y/Z-modified duplexes exhibit emission peaks of varying broadness at $\sim 390/402$ nm (V), $\sim 381/398$ nm (Y), and $\sim 376/396/416$ nm (Z), respectively, which are typical emission maxima for electronically isolated pyrene units (Figure 3). As expected for duplexes modified with the 1-ethynylpyrene fluorophore,³⁵ the duplex between W5 and complementary DNA exhibits broad red-shifted emission centered around ~ 465 nm, which is indicative of strong electronic coupling

between the pyrene and nucleobase moiety. Interestingly, the emission intensities of pyrene-functionalized ONs V5/W5/Y5/Z5 increase upon binding to complementary DNA (~ 3.8 -, ~ 3.9 -, ~ 3.1 -, and ~ 51 -fold increases for V5, W5, Y5 and Z5, respectively, Figure 3). In contrast, much smaller increases are observed upon hybridization with mismatched DNA targets. The intensity differences are most likely due to different positioning of the pyrene moieties in matched vs mismatched duplexes, in a manner similar to that proposed for the corresponding DNA analogues of monomers V/W/Y/Z.^{18g,j,35b} Thus, the pyrene moieties likely point into the nonquenching environment of the major groove in matched duplexes (nucleobase in *anti* conformation), while they are intercalating into mismatched duplexes leading to nucleobase-mediated quenching³⁶ of pyrene fluorescence (nucleobase in *syn* conformation). Regardless of the mechanism, the results strongly suggest that V/W/Y/Z-modified ONs are promising probes for the detection of nucleic acid targets and fluorescent discrimination of single-nucleotide polymorphisms (SNPs).

Duplexes between perylene-functionalized X5 and complementary DNA display broad emission maxima at ~ 487 and ~ 517 nm, whereas the emission maxima are red-shifted by ~ 10 nm in mismatched DNA duplexes (Figure 3). The emission intensity of X5 does not change significantly upon binding with




Figure 3. Steady-state fluorescence emission spectra of single-stranded **B5** ONs (5'-CG CAA **C**BC AAC GC) and the corresponding duplexes with fully complementary or singly mismatched DNA strands (mismatched nucleotide opposite of modification is specified). Conditions: λ_{ex} 344 nm (VS/Y5/Z5), λ_{ex} 375 nm (W5), λ_{ex} 448 nm (X5); $T = 5^\circ\text{C}$. Note that different axis scales are used.

complementary DNA but is reduced by 30–60% upon binding to mismatched targets, presumably due to nucleobase-mediated quenching of intercalating perylene units.

Recently, we examined the SNP-discriminating properties of V-modified ONs and compared them to probes modified with the corresponding DNA analogue of monomer **V**.³⁷ We found that there are distinct advantages to conjugating the 1-pyrenecarboxamido fluorophore to the C5-position of LNA-U, including (i) greater increases in fluorescence intensity upon target binding, (ii) formation of more brightly fluorescent duplexes, and (iii) stricter fluorescent discrimination of DNA targets with SNP sites. Force field calculations suggested that the extreme pucker of the LNA skeleton influences the rotational freedom around the N1–C1' glycosyl bond due to steric hindrance between H6 and H3', leading to different positioning and modulated photophysical properties of the C5-fluorophore relative to the analogous DNA monomer.³⁷

Direct comparison of **Y5** and **Z5** with the corresponding DNA-based probes **Y5d** and **Z5d**^{18j} (for structures of the DNA analogues of **V**/**Y**/**Z** monomers, see Figure S4 in the Supporting Information) reveals similar advantages (Figure 4). Thus, the results suggest that conjugation of fluorophores to the C5 position of LNA monomers is an effective strategy toward the generation of building blocks with interesting photophysical properties.

The large increases in fluorescence intensity upon hybridization of **Z5** with complementary targets prompted us to examine the potential of **Z**-modified ONs as hybridization probes³⁸ in greater detail. Three additional 13-mer ONs were therefore prepared in which the nucleotides flanking monomer **Z** were systematically varied (Table S4, Supporting Information). Although the increases in fluorescence intensities upon hybridization with DNA targets are less pronounced (4–17-fold, Figure 5) and the resulting duplexes are significantly less fluorescent than with **Z5**,³⁹ moderate to excellent fluorescent discrimination of mismatched DNA targets is observed with all **Z**-modified probes (discrimination factors from 1.5 to 48, Figure 5). Accordingly, **Z**-modified ONs constitute an interesting addition to the existing pool of pyrene-based hybridization probes.^{18j,40}

CONCLUSION

The hybridization characteristics and enzymatic stabilities of ONs modified with LNA uridines can be extensively modulated through conjugation of different entities to the C5 position of the nucleobase. Only two extra steps, relative to conventional LNA synthesis, are needed. Monomers that are conjugated to small alkynyl substituents result in significantly greater target affinity and specificity than regular LNA monomers. Conjugation of bulky moieties confers complete protection against 3'-exonucleases but also decreases target affinity. ONs modified




Figure 4. Fluorescence intensity of single-stranded probes (SSPs) in the presence or absence of complementary or singly mismatched DNA/RNA strands. Mismatched nucleotide opposite of modification is specified. Hybridization-induced increases and discrimination factors (defined as the fluorescence intensity of duplexes with complementary DNA/RNA divided by the intensity of SSPs or duplexes with mismatched DNA/RNA, respectively) are given above the corresponding histograms. Intensity recorded at λ_{em} 382 nm for Y5/Y5d and λ_{em} 377 nm for Z5/Z5d at $T = 5^\circ\text{C}$. Note that different y-axis scales are used.




Figure 5. Fluorescence intensity of single-stranded probes (SSPs) in the presence or absence of complementary or singly mismatched DNA strands. Mismatched nucleotide opposite of modification is specified. Hybridization-induced increases and discrimination factors are given above the corresponding histograms. Target: 5'-CG CAA BZB AAC GC, where B = C/A/G/T for ON5–8, respectively. Intensity recorded at λ_{em} 377 nm at $T = 5^\circ\text{C}$.

with C5-fluorophore-functionalized LNA uridines display improved photophysical characteristics relative to the corresponding DNA-based probes, including greater hybridization-induced increases in fluorescence intensity, formation of more brightly fluorescent duplexes, and strict fluorescent discrimination of single-nucleotide polymorphisms.^{20b} These properties render C5-functionalized LNA as promising building blocks for RNA-targeting applications and nucleic acid diagnostics,

although concerns regarding the potential toxicity of C5-alkynyl entities⁴¹ must be alleviated prior to biological evaluation.

The present study suggests that it is possible to combine desirable properties from LNA (target affinity/specificity) and C5-functionalized DNA monomers (positioning of functional entities in the major groove) into one compound class. The subsequent article in this issue demonstrates that the properties of ONs modified with α -L-LNA uridines also can be modulated through functionalization of the nucleobase.⁴² We therefore anticipate that C5 functionalization of pyrimidines will serve as a general and synthetically straightforward approach for modulation of pharmacodynamic and pharmacokinetic properties of oligonucleotides modified with LNA^{8–10,13} or other conformationally restricted monomers.^{1–7,16} Efforts aiming at delineating whether the biophysical properties of LNA purines also can be improved through functionalization of the nucleobase are ongoing, and the results from these studies will be reported shortly.

EXPERIMENTAL SECTION

Representative Protocol for EDC-Mediated Coupling of Carboxylic Acids with Propargylamine to Furnish Alkynes Ae–Ag⁴³ Used in Sonogashira Couplings. The appropriate carboxylic acid and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) were added to propargylamine in anhydrous CH_2Cl_2 , and the reaction mixture was stirred under an argon atmosphere until analytical TLC indicated full conversion (quantities, volumes, reaction time, and temperature are specified below). At this point, CH_2Cl_2 (40 mL) was added and the organic phase was washed with 5% aqueous citric acid (2×20 mL) and H_2O (20 mL). The aqueous phase was back-extracted with CH_2Cl_2 (25 mL), the combined organic layers were concentrated to dryness, and the resulting residue was purified by column chromatography (0–4% MeOH in CH_2Cl_2) to afford the desired product (quantities and yields specified below).

***N*-(Prop-2-ynyl)-2-(adamant-1-yl)ethanamide (Ae).** 1-Adamantanecetic acid (1.60 g, 8.24 mmol), EDC·HCl (1.80 g, 9.42 mmol), and propargylamine (0.60 mL, 9.38 mmol) in anhydrous CH_2Cl_2 (30 mL) were set up, reacted (14 h at room temperature), and worked up, and the product was purified as described above to afford alkyne Ae⁴³ (1.40 g, 76%) as a white solid material: $R_f = 0.8$ (10% MeOH/ CH_2Cl_2 , v/v); MALDI-HRMS m/z 254.1527 ($[\text{M} + \text{Na}]^+$, $\text{C}_{15}\text{H}_{21}\text{NO}\cdot\text{Na}^+$, calcd 254.1515); ^1H NMR (CDCl_3) δ 5.56 (br s, 1H, NH), 4.01 (dd, 2H, $J = 5.2$ Hz, 2.5 Hz, CH_2NH), 2.19 (t, 1H, $J = 2.5$ Hz, $\text{HC}\equiv\text{C}$), 1.93–1.97 (m, 3H, $3 \times \text{CH}$), 1.92 (s, 2H, CH_2CONH), 1.58–1.70 (12H, $6 \times \text{CH}_2$ -ada); ^{13}C NMR (CDCl_3) δ 170.8, 80.0, 71.6 ($\text{HC}\equiv\text{C}$), 51.6 (CH_2CONH), 42.8 (CH_2 -ada), 37.0 (CH_2 -ada), 33.1, 29.2 (CH_2NH), 28.9 (CH -ada).

***N*-(Prop-2-ynyl)dodecanamide (Af).** Lauric acid (dodecanoic acid, 1.60 g, 8.00 mmol), EDC·HCl (1.80 g, 9.42 mmol), and propargylamine (0.60 mL, 9.38 mmol) in anhydrous CH_2Cl_2 (30 mL) were set up, reacted (12 h at room temperature), and worked up, and the product was purified as described above to afford alkyne Af⁴³ (1.40 g, 76%) as a white solid material: $R_f = 0.8$; MALDI-HRMS m/z 260.1978 ($[\text{M} + \text{Na}]^+$, $\text{C}_{15}\text{H}_{27}\text{NO}\cdot\text{Na}^+$, calcd 260.1985); ^1H NMR (CDCl_3) δ 5.66 (bs, ex, 1H, NH), 4.03 (dd, 2H, $J = 5.0$ Hz, 2.5 Hz, $\text{CH}_2\text{C}\equiv\text{CH}$), 2.19 (t, 1H, $J = 2.5$ Hz, $\text{HC}\equiv\text{C}$), 2.16 (2d, 2H, $J = 7.7$ Hz, CH_2CO), 1.61 (quintet, 2H, $J = 7.7$ Hz, $\text{CH}_2\text{CH}_2\text{CO}$), 1.20–1.30 (m, 16H, $8 \times \text{CH}_2$), 0.85 (t, 3H, $J = 6.5$ Hz, CH_3); ^{13}C NMR (CDCl_3) δ 172.9, 79.9, 71.7, 36.7 (CH_2CO), 32.1 (CH_2), 29.8 (CH_2), 29.7 (CH_2), 29.53 (CH_2), 29.47 (CH_2), 29.4 ($\text{CH}_2\text{C}\equiv\text{CH}$), 25.8 ($\text{CH}_2\text{CH}_2\text{CO}$), 22.9, 14.3 (CH_3). ^1H NMR data are in agreement with literature reports.⁴⁴

***N*-(Prop-2-ynyl)octadecanamide (Ag).** Stearic acid (octadecanoic acid, 1.42 g, 5.00 mmol), EDC·HCl (1.15 g, 6.00 mmol), and propargylamine (0.40 mL, 6.25 mmol) in anhydrous CH_2Cl_2 (30 mL) were set up, reacted (12 h at room temperature), and worked up, and the product was purified as described above to afford alkyne Ag⁴³ (1.40 g, 87%) as a white solid material: $R_f = 0.1$ (CH_2Cl_2); FAB-

HRMS m/z 321.3020 ($[M]^+$, $C_{21}H_{39}NO^+$, calcd 321.3032); 1H NMR ($CDCl_3$) δ 5.54 (br s, 1H, ex, NH), 4.03 (dd, 2H, $J = 5.5$ Hz, 2.5 Hz, CH_2NH), 2.20 (t, 1H, $J = 2.5$ Hz, $HC\equiv C$), 2.17 (t, 2H, $J = 7.5$ Hz, CH_2CO), 1.61 (quintet, 2H, $J = 7.5$ Hz, CH_2CH_2CO), 1.23–1.27 (m, 28H, $14 \times CH_2$), 0.87 (t, 1H, $J = 7.0$ Hz, CH_3); ^{13}C NMR ($CDCl_3$) δ 172.7, 79.7, 71.5 ($HC\equiv C$), 36.5 (CH_2CO), 31.9 (CH_2), 29.69 (CH_2), 29.684 (CH_2), 29.677 (CH_2), 29.66 (CH_2), 29.65 (CH_2), 29.64 (CH_2), 29.59 (CH_2), 29.46 (CH_2), 29.35 (CH_2), 29.31 (CH_2), 29.2 (CH_2), 29.1 (CH_2NH), 25.5 (CH_2CH_2CONH), 22.7 (CH_2), 14.1 (CH_3). The NMR data are in excellent agreement with literature reports.⁴⁵

(1*S*,3*R*,4*R*,7*S*)-7-Hydroxy-1-hydroxymethyl-3-(5-iodoracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (2). To a solution of nucleoside 1²³ (4.00 g, 15.62 mmol) in glacial AcOH (150 mL) were added iodine (2.40 g, 9.44 mmol) and ceric ammonium nitrate (4.26 g, 7.77 mmol), and the reaction mixture was stirred at 80 °C for ~40 min. After it was cooled to room temperature, the mixture was evaporated to dryness and the resulting residue was suspended in MeOH (150 mL). The mixture was concentrated and the resulting residue adsorbed on silica gel and purified by column chromatography (0–15% MeOH/ CH_2Cl_2 , v/v) to afford nucleoside 2 (5.21 g, 87%) as a white solid material: $R_f = 0.4$ (10% MeOH/ CH_2Cl_2 , v/v); FAB-HRMS m/z 382.9732 ($[M + H]^+$, $C_{10}H_{11}IN_2O_6H^+$, calcd 382.9735); 1H NMR ($DMSO-d_6$) δ 11.69 (s, 1H, ex, NH), 8.13 (s, 1H, H6), 5.65 (d, 1H, ex, $J = 4.5$ Hz, 3'-OH), 5.40 (s, 1H, H1'), 5.27 (t, 1H, ex, $J = 5.4$ Hz, 5'-OH), 4.14 (s, 1H, H2'), 3.91 (d, 1H, $J = 4.5$ Hz, H3'), 3.79–3.82 (d, 1H, $J = 8.5$ Hz, H5''), 3.68–3.75 (m, 2H, H5'), 3.58–3.62 (d, 1H, $J = 8.5$ Hz, H5'); ^{13}C NMR ($DMSO-d_6$) δ 160.5, 149.6, 143.5 (C6), 88.8, 86.4 (C1'), 78.5 (C2'), 70.8 (C5''), 68.4, 68.2 (C3'), 55.3 (C5').

(1*R*,3*R*,4*R*,7*S*)-1-(4,4'-Dimethoxytrityloxymethyl)-7-hydroxy-3-(5-iodoracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (3). Diol 2 (5.00 g, 13.0 mmol) was coevaporated with anhydrous pyridine (100 mL) and redissolved in anhydrous pyridine (100 mL). To this was added 4,4'-dimethoxytrityl chloride (DMTr-Cl, 5.75 g, 16.9 mmol), and the reaction mixture was stirred at room temperature for 16 h, whereupon solvent was evaporated off. The residue was dissolved in CH_2Cl_2 (300 mL) and washed with saturated aqueous $NaHCO_3$ (300 mL). The aqueous layer was back-extracted with CH_2Cl_2 (2 \times 100 mL), and the combined organic layer was washed with saturated aqueous $NaHCO_3$ (100 mL), dried (Na_2SO_4), evaporated to near dryness, and coevaporated with toluene/absolute EtOH (100 mL, 1/2, v/v). The resulting residue was purified by column chromatography (0–5% MeOH in CH_2Cl_2 , v/v) to afford key intermediate 3 (7.52 g, 82%) as a slightly yellow solid material: $R_f = 0.5$ (5% MeOH in CH_2Cl_2 , v/v); FAB-HRMS m/z 684.0977 ($[M]^+$, $C_{31}H_{29}IN_2O_8^+$, calcd 684.0969); 1H NMR ($DMSO-d_6$) δ 11.74 (s, 1H, ex, NH), 7.96 (s, 1H, H6), 7.23–7.45 (m, 9H, Ar), 6.91 (d, 4H, $J = 8.5$ Hz, Ar), 5.70 (d, 1H, ex, $J = 4.5$ Hz, 3'-OH), 5.44 (s, 1H, H1'), 4.24 (s, 1H, H2'), 4.07 (d, 1H, $J = 4.5$ Hz, H3'), 3.74–3.76 (m, 8H, 2 \times OCH_3 , 2 \times H5''), 3.39–3.42 (d, 1H, $J = 11.0$ Hz, H5'), 3.28–3.31 (d, 1H, $J = 11.0$ Hz, H5', overlap with H_2O); ^{13}C NMR ($DMSO-d_6$) δ 160.5, 158.1, 158.0, 149.7, 144.6, 142.7 (C6), 135.3, 135.2, 129.7 (Ar), 129.6 (Ar), 127.9 (Ar), 127.5 (Ar), 126.6 (Ar), 113.3 (Ar), 87.5, 86.9 (C1'), 85.6, 78.8 (C2'), 71.3 (C5''), 69.4 (C3'), 68.9, 58.9 (C5'), 55.0 (CH_3O).

Representative Protocol for Sonogashira Couplings (4a–j). Key intermediate 3, $Pd(PPh_3)_4$, CuI, and alkyne were added to anhydrous DMF (quantities and volumes specified below), and the reaction chamber was degassed and placed under an argon atmosphere. To this was added Et_3N , and the reaction mixture was stirred in the dark until analytical TLC indicated full conversion of the starting material (reaction time and temperature specified below), whereupon solvents were evaporated off. The resulting residue was taken in up in EtOAc (100 mL) and washed with brine (2 \times 50 mL) and saturated aqueous $NaHCO_3$ (50 mL). The combined aqueous phase was back-extracted with EtOAc (100 mL), the combined organic phase dried (Na_2SO_4) and evaporated to dryness, and the resulting residue purified by column chromatography (0–5% MeOH in CH_2Cl_2 (v/v) to afford the desired product.

(1*R*,3*R*,4*R*,7*S*)-1-(4,4'-Dimethoxytrityloxymethyl)-7-hydroxy-3-[5-(trimethylsilylethynyl)uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane

(4a). Nucleoside 3 (0.68 g, 1.00 mmol), $Pd(PPh_3)_4$ (120 mg, 0.10 mmol), CuI (40 mg, 0.20 mmol), trimethylsilylacetylene (294 mg, 0.42 mL, 3.00 mmol), and Et_3N (0.60 mL, 4.27 mmol) in DMF (10 mL) were reacted as described in the representative Sonogashira protocol, and the mixture was stirred at room temperature for 12 h. After workup and purification, nucleoside 4a (0.56 g, 85%) was obtained as a brown solid material. $R_f = 0.5$ (5% MeOH in CH_2Cl_2 , v/v); ESI-HRMS m/z 677.2297 ($[M + Na]^+$, $C_{36}H_{38}N_2O_8SiNa^+$, calcd 677.2290); 1H NMR ($DMSO-d_6$) δ 11.69 (s, 1H, ex, NH), 7.86 (s, 1H, H6), 7.20–7.45 (m, 9H, Ar), 6.89 (d, 4H, $J = 8.5$ Hz, Ar), 5.72 (d, 1H, ex, $J = 4.5$ Hz, 3'-OH), 5.39 (s, 1H, H1'), 4.28 (s, 1H, H2'), 4.08 (d, 1H, $J = 4.5$ Hz, H3'), 3.75–3.80 (m, 2H, 2 \times H5''), 3.73 (s, 6H, 2 \times OCH_3), 3.40–3.43 (d, 1H, $J = 11.0$ Hz, H5'), 3.30–3.33 (d, 1H, $J = 11.0$ Hz, H5', overlap with H_2O signal), -0.04 (s, 9H, Me_3Si); ^{13}C NMR ($DMSO-d_6$) δ 161.5, 158.05, 158.03, 148.9, 144.6, 142.5 (C6), 135.4, 135.2, 129.7 (Ar), 129.5 (Ar), 127.8 (Ar), 127.6 (Ar), 126.6 (Ar), 113.2 (Ar), 97.9, 97.5, 96.9, 87.7, 87.1 (C1'), 85.5, 78.6 (C2'), 71.3 (C5''), 69.5 (C3'), 58.9 (C5'), 55.0 (CH_3O), -0.47 (Me_3Si).

(1*R*,3*R*,4*R*,7*S*)-1-(4,4'-Dimethoxytrityloxymethyl)-3-(5-ethynyluracil-1-yl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptane (4b). To a solution of nucleoside 4a (0.53 g, 0.81 mmol) in THF (20 mL) was added tetrabutylammonium fluoride in THF (TBAF, 1 M, 1.2 mL, 1.2 mmol), and the reaction mixture was stirred at room temperature for 2 h. EtOAc (50 mL) was added and the organic phase washed with brine (2 \times 30 mL) and H_2O (30 mL). The aqueous phase was back-extracted with EtOAc (30 mL). The combined organic phase was dried (Na_2SO_4) and evaporated to dryness and the resulting residue purified by column chromatography (0–5% MeOH in CH_2Cl_2 , v/v) to afford nucleoside 4b (0.37 g, 78%) as a lightly brown solid material: $R_f = 0.4$ (5% MeOH/ CH_2Cl_2 , v/v); ESI-HRMS m/z 621.1666 ($[M + K]^+$, $C_{33}H_{30}N_2O_8K^+$, calcd 621.1634); 1H NMR ($DMSO-d_6$) δ 11.70 (s, 1H, ex, NH), 7.88 (s, 1H, H6), 7.21–7.45 (m, 9H, Ar), 6.88–6.92 (m, 4H, Ar), 5.70 (d, 1H, ex, $J = 4.5$ Hz, 3'-OH), 5.45 (s, 1H, H1'), 4.27 (s, 1H, H2'), 4.05 (d, 1H, $J = 4.5$ Hz, H3'), 3.95 (s, 1H, CH), 3.77 (s, 2H, 2 \times H5''), 3.75 (s, 6H, 2 \times CH_3O), 3.43–3.45 (d, 1H, $J = 11.0$ Hz, H5'), 3.28–3.31 (d, 1H, $J = 11.0$ Hz, H5', overlap with H_2O signal); ^{13}C NMR ($DMSO-d_6$) δ 161.7, 158.1, 149.0, 144.6, 142.2 (C6), 135.3, 135.2, 129.7 (Ar), 129.6 (Ar), 127.9 (Ar), 127.5 (Ar), 126.7 (Ar), 113.3 (Ar), 97.2, 87.5, 86.9 (C1'), 85.7, 83.6, 78.9 (C2'), 76.2, 71.4 (C5''), 69.4 (C3'), 59.0 (C5'), 55.0 (CH_3O).

(1*R*,3*R*,4*R*,7*S*)-3-[5-(3-Benzoyloxypropyn-1-yl)uracil-1-yl]-1-(4,4'-dimethoxytrityloxymethyl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptane (4c). Nucleoside 3 (0.50 g, 0.73 mmol), $Pd(PPh_3)_4$ (90 mg, 0.07 mmol), CuI (30 mg, 0.14 mmol), prop-2-ynyl benzoate⁴⁶ (180 mg, 1.12 mmol), and Et_3N (0.40 mL, 2.84 mmol) in DMF (10 mL) were reacted as described in the representative Sonogashira protocol, and the reaction mixture was stirred at room temperature for 12 h. After workup and purification, nucleoside 4c (0.37 g, 70%) was obtained as a light brown solid material: $R_f = 0.5$ (5% MeOH in CH_2Cl_2 , v/v); ESI-HRMS m/z 739.2289 ($[M + Na]^+$, $C_{41}H_{36}N_2O_{10}Na$, calcd 739.2262); 1H NMR ($DMSO-d_6$) δ 11.72 (s, 1H, ex, NH), 7.91–7.93 (d, 2H, $J = 7.7$ Hz, Bz_{ortho}), 7.89 (s, 1H, H6), 7.65–7.70 (t, 1H, $J = 7.7$ Hz, Bz_{para}), 7.49–7.54 (t, 2H, $J = 7.7$ Hz, Bz_{meta}), 7.42–7.46 (d, 2H, $J = 8.5$ Hz, DMTr), 7.28–7.34 (m, 6H, DMTr), 7.18–7.22 (t, 1H, $J = 7.5$ Hz, DMTr), 6.87–6.91 (2d, 4H, $J = 9.0$ Hz, DMTr), 5.74 (d, 1H, ex, $J = 4.5$ Hz, 3'-OH), 5.42 (s, 1H, H1'), 4.93–4.97 (d, 1H, $J = 16.0$ Hz, CH_2OBz), 4.86–4.90 (d, 1H, $J = 16.0$ Hz, CH_2OBz), 4.25 (s, 1H, H2'), 4.10 (d, 1H, $J = 4.5$ Hz, H3'), 3.78–3.82 (d, 1H, $J = 8.0$ Hz, H5''), 3.75–3.76 (d, 1H, $J = 8.0$ Hz, H5'), 3.71 (s, 6H, 2 \times CH_3O), 3.53–3.56 (d, 1H, $J = 11.0$ Hz, H5'), 3.27–3.30 (d, 1H, $J = 11.0$ Hz, H5', overlap with H_2O); ^{13}C NMR ($DMSO-d_6$) δ 164.9, 161.6, 158.1, 158.0, 149.0, 144.6, 142.7 (C6), 135.4, 135.0, 133.5 (CBz_{para}), 129.7 (DMTr), 129.6 (DMTr), 129.2 (CBz_{ortho}), 129.0, 128.7 (CBz_{meta}), 127.8 (DMTr), 127.5 (DMTr), 126.6 (DMTr), 113.20 (DMTr), 113.17 (DMTr), 96.8, 87.6, 86.9 (C1'), 86.3, 85.6, 79.2, 78.7 (C2'), 71.3 (C5''), 69.4 (C3'), 58.7 (C5'), 54.9 (CH_3O), 53.1 (CH_2OBz).

(1*R*,3*R*,4*R*,7*S*)-1-(4,4'-Dimethoxytrityloxymethyl)-7-hydroxy-3-[5-(3-trifluoroacetylaminopropyn-1-yl)uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (4d). Nucleoside 3 (0.50 g, 0.73 mmol), $Pd(PPh_3)_4$

(90 mg, 0.07 mmol), CuI (30 mg, 0.14 mmol), 2,2,2-trifluoro-*N*-(prop-2-ynyl)acetamide⁴⁷ (180 mg, 1.46 mmol), and Et₃N (0.40 mL, 2.84 mmol) in DMF (10 mL) were reacted as described in the representative Sonogashira protocol, and the mixture was stirred at room temperature for 12 h. After workup and purification, nucleoside **4d** (0.41 g, 80%) was obtained as a brown solid material: *R*_f = 0.5 (5% MeOH in CH₂Cl₂, v/v); ESI-HRMS *m/z* 714.2247 ([M+Li]⁺, C₃₆H₃₂F₃N₃O₉Li⁺, calcd 714.2245); ¹H NMR (DMSO-*d*₆) δ 11.69 (s, 1H, ex, NH(U)), 9.95 (t, 1H, ex, *J* = 5.5 Hz, NHCH₂), 7.78 (s, 1H, H6), 7.22–7.46 (m, 9H, Ar), 6.90 (dd, 4H, *J* = 9.0 Hz, 3.5 Hz, Ar), 5.73 (d, 1H, ex, *J* = 4.5 Hz, 3'-OH), 5.41 (s, 1H, H1'), 4.25 (s, 1H, H2'), 3.97–4.10 (m, 3H, H3', CH₂NH), 3.79–3.83 (2d, 2H, *J* = 8.0 Hz, 2 × H5''), 3.74 (s, 6H, 2 × CH₃O), 3.56–3.58 (d, 1H, *J* = 11.0 Hz, H5'), 3.26–3.28 (d, 1H, *J* = 11.0 Hz, H5'); ¹³C NMR (DMSO-*d*₆) δ 161.6, 158.11, 158.06, 155.9 (q, *J* = 36.1 Hz, COCF₃), 149.0, 144.6, 142.1 (C6), 135.4, 134.9, 129.8 (Ar), 129.6 (Ar), 127.8 (Ar), 127.5 (Ar), 126.6 (Ar), 115.6 (q, *J* = 287 Hz, CF₃), 113.22 (Ar), 113.20 (Ar), 97.2, 87.6, 87.2, 86.9 (C1'), 85.6, 78.7 (C2'), 75.4, 71.3 (C5''), 69.6 (C3'), 59.1 (C5'), 55.0 (CH₃O), 29.4 (CH₂NH); ¹⁹F (DMSO-*d*₆, 470 MHz) δ -74.7.

(1*R*,3*R*,4*R*,7*S*)-3-[5-(3-(1-Adamantylmethylcarbonyl)aminopropyn-1-yl)uracil-1-yl]-1-(4,4'-dimethoxytrityloxymethyl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptane (**4e**). Nucleoside **3** (0.50 g, 0.73 mmol), Pd(PPh₃)₄ (90 mg, 0.05 mmol), CuI (30 mg, 0.10 mmol), *N*-(prop-2-ynyl)-1-adamantaneacetamide (220 mg, 1.00 mmol), and Et₃N (0.40 mL, 2.84 mmol) in DMF (10 mL) were reacted as described in the representative Sonogashira protocol, and the mixture was stirred at room temperature for 12 h. After workup and purification, nucleoside **4e** (0.43 g, 76%) was obtained as a white solid material: *R*_f = 0.5 (5% MeOH in CH₂Cl₂, v/v); MALDI-HRMS *m/z* 810.3330 ([M + Na]⁺, C₄₆H₄₉N₃O₉Na⁺, calcd 810.3361); ¹H NMR (DMSO-*d*₆) δ 11.66 (s, 1H, ex, NH(U)), 8.00 (t, 1H, ex, *J* = 5.5 Hz, NHCO), 7.75 (s, 1H, H6), 7.42–7.45 (m, 2H, Ar), 7.23–7.34 (m, 7H, Ar), 6.89–6.92 (2d, 4H, *J* = 9.0 Hz, Ar), 5.72 (d, 1H, ex, *J* = 4.5 Hz, 3'-OH), 5.42 (s, 1H, H1'), 4.24 (s, 1H, H2'), 4.01 (d, 1H, *J* = 4.5 Hz, H3'), 3.87–3.93 (dd, 1H, *J* = 17.5 Hz, 5.5 Hz, CH₂NHCO), 3.82–3.87 (dd, 1H, *J* = 17.5 Hz, 5.5 Hz, CH₂NHCO), 3.78–3.82 (2d, 2H, *J* = 8.2 Hz, H5''), 3.75 (s, 3H, CH₃O), 3.74 (s, 3H, CH₃O), 3.54–3.56 (d, 1H, *J* = 11.0 Hz, H5'), 3.27–3.30 (d, 1H, *J* = 11.0 Hz, H5', overlap with H₂O), 1.82–1.87 (m, 5H, 3 × ada-CH/CH₂CONH), 1.53–1.63 (m, 12H, 6 × ada-CH₂); ¹³C NMR (DMSO-*d*₆) δ 169.6, 161.7, 158.12, 158.07, 149.0, 144.7, 141.5 (C6), 135.4, 134.9, 129.8 (Ar), 129.6 (Ar), 127.9 (Ar), 127.5 (Ar), 126.7 (Ar), 113.24 (Ar), 113.23 (Ar), 97.7, 89.6, 87.5, 86.9 (C1'), 85.6, 78.8 (C2'), 74.2, 71.4 (C5''), 69.6 (C3'), 59.1 (C5'), 54.9 (CH₃O), 49.5 (CH₂CONH), 42.0 (ada-CH₂), 36.4 (ada-CH₂), 32.3, 28.4 (CH₂NHCO), 28.0 (ada-CH).

(1*R*,3*R*,4*R*,7*S*)-1-(4,4'-Dimethoxytrityloxymethyl)-3-[5-(3-dodecylaminopropyn-1-yl)uracil-1-yl]-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptane (**4f**). Nucleoside **3** (200 mg, 0.29 mmol), Pd(PPh₃)₄ (34 mg, 0.03 mmol), CuI (11 mg, 0.06 mmol), *N*-(prop-2-ynyl)lauroylamide (110 mg, 0.44 mmol), and Et₃N (0.18 mL, 1.29 mmol) in DMF (3 mL) were reacted as described in the representative Sonogashira protocol, and the mixture was stirred at room temperature for 15 h. After workup and purification, nucleoside **4f** (202 mg, 87%) was obtained as a white solid material: *R*_f = 0.2 (5% MeOH in CH₂Cl₂, v/v); MALDI-HRMS *m/z* 816.3835 ([M + Na]⁺, C₄₆H₅₅N₃O₉Na⁺, calcd 816.3831); ¹H NMR (DMSO-*d*₆) δ 11.67 (s, 1H, ex, NH(U)), 8.08 (t, 1H, *J* = 5.4 Hz, NHCH₂), 7.76 (s, 1H, H6), 7.22–7.46 (m, 9H, Ar), 6.87–6.96 (m, 4H, Ar), 5.72 (d, 1H, ex, *J* = 4.7 Hz, 3'-OH), 5.42 (s, 1H, H1'), 4.25 (s, 1H, H2'), 4.03 (d, 1H, *J* = 4.7 Hz, H3'), 3.88–3.94 (dd, 1H, *J* = 12.4 Hz, 5.4 Hz, CH₂NHCO), 3.81–3.88 (dd, 1H, *J* = 12.4 Hz, 5.4 Hz, CH₂NHCO), 3.78–3.82 (2d, 2H, *J* = 8.0 Hz, H5''), 3.75 (s, 6H, 2 × CH₃O), 3.55–3.57 (d, 1H, *J* = 10.9 Hz, H5'), 3.27–3.30 (d, 1H, *J* = 10.9 Hz, H5', overlap with H₂O), 2.05 (t, 2H, *J* = 7.4 Hz, CH₂CONH), 1.43–1.48 (m, 2H, CH₂CH₂CONH), 1.19–1.28 (m, 16H, 8 × CH₂), 0.85 (t, 3H, *J* = 7.0 Hz, CH₃); ¹³C NMR (DMSO) δ 171.7, 161.7, 158.11, 158.06, 149.0, 144.6, 141.6 (C6), 135.4, 134.9, 129.8 (Ar), 129.6 (Ar), 127.9 (Ar), 127.5 (Ar), 126.6 (Ar), 113.22 (Ar), 113.21 (Ar), 97.7, 89.5, 87.5, 86.9 (C1'), 85.6, 78.8 (C2'), 74.3, 71.4 (C5''), 69.6 (C3'), 59.0 (C5'), 55.0 (CH₃O), 35.0

(CH₂CONH), 31.2 (CH₂), 28.94 (CH₂), 28.92 (CH₂), 28.8 (CH₂), 28.7 (CH₂), 28.63 (CH₂), 28.60 (CH₂), 28.52 (CH₂NHCO), 25.0 (CH₂CH₂CONH), 22.0 (CH₂CH₃), 13.9 (CH₃).

(1*R*,3*R*,4*R*,7*S*)-1-(4,4'-Dimethoxytrityloxymethyl)-7-hydroxy-3-[5-(3-octadecanoylamino propyn-1-yl)uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (**4g**). Nucleoside **3** (0.34 g, 0.50 mmol), Pd(PPh₃)₄ (60 mg, 0.05 mmol), CuI (20 mg, 0.10 mmol), *N*-(prop-2-ynyl)stearamide (0.28 g, 1.00 mmol), and Et₃N (0.30 mL, 2.13 mmol) in DMF (10 mL) were reacted as described in the representative Sonogashira protocol, and the mixture was stirred at 40 °C for 6 h. After workup and purification, nucleoside **4g** (0.29 g, 68%) was obtained as a brown solid material, which was used in the next step without further purification: *R*_f = 0.5 (5% MeOH in CH₂Cl₂, v/v); FAB-HRMS *m/z* 877.4844 ([M]⁺, C₅₂H₆₇N₃O₉, calcd 877.4877); ¹H NMR (CDCl₃) δ 9.45 (br s, 1H, ex, NH(U)), 8.05 (s, 1H, H6), 7.22–7.50 (m, 9H, Ar), 6.85–6.89 (dd, 4H, *J* = 9.0 Hz, 1.5 Hz, Ar), 5.56–5.59 (m, 2H, 1 ex, H1', NHCH₂), 4.53 (s, 1H, H2'), 4.29 (s, 1H, H3'), 3.78–4.01 (m, 10H, 2 × H5', CH₂NH, 2 × CH₃O), 3.53–3.57 (d, 1H, *J* = 11.0 Hz, H5'), 3.49–3.52 (d, 1H, *J* = 11.0 Hz, H5'), 3.35 (br s, 1H, ex, 3'-OH), 1.85–1.89 (m, 2H, CH₂CONH), 1.44–1.51 (m, 2H, CH₂CH₂CONH), 1.23–1.28 (m, 28H, 14 × CH₂), 0.89 (t, 3H, *J* = 6.5 Hz, CH₃); ¹³C NMR (CDCl₃) δ 172.7, 162.1, 158.69, 158.67, 148.6, 144.6, 141.9 (C6), 135.5, 135.4, 130.02 (Ar), 130.01 (Ar), 128.1 (Ar), 128.0 (Ar), 127.0 (Ar), 113.45 (Ar), 113.43 (Ar), 99.1, 89.9, 88.4, 87.4 (C1'), 86.6, 79.1 (C2'), 74.2, 71.8 (C5''), 70.5 (C3'), 58.5 (C5'), 55.3 (CH₃O), 36.1 (CH₂CONH), 31.9 (CH₂), 29.9 (CH₂NH), 29.69 (CH₂), 29.68 (CH₂), 29.66 (CH₂), 29.6 (CH₂), 29.5 (CH₂), 29.4 (CH₂), 29.34 (CH₂), 29.33 (CH₂), 25.4 (CH₂CH₂CONH), 22.7 (CH₂), 14.1 (CH₃). A small impurity of silicon grease was observed at ~1 ppm in the ¹³C NMR.⁴⁸

(1*R*,3*R*,4*R*,7*S*)-3-[5-(3-Cholesterylcarbonylaminopropyn-1-yl)uracil-1-yl]-1-(4,4'-dimethoxytrityloxymethyl)-7-hydroxy-2,5-dioxabicyclo[2.2.1]heptane (**4h**). Nucleoside **3** (0.34 g, 0.50 mmol), Pd(PPh₃)₄ (60 mg, 0.05 mmol), CuI (20 mg, 0.10 mmol), cholesterylprop-2-ynylcarbamate⁴⁹ (0.47 g, 1.00 mmol), and Et₃N (0.30 mL, 2.13 mmol) in DMF (8 mL) were reacted as described in the representative Sonogashira protocol, and the mixture was stirred at room temperature for 12 h. After workup and purification, nucleoside **4h** (0.27 g, 53%) was obtained as a brown solid material, which was used in the next step without further purification: *R*_f = 0.5 (5% MeOH in CH₂Cl₂, v/v); FAB-HRMS *m/z* 1046.5560 ([M + Na]⁺, C₆₂H₇₇N₃O₁₀Na⁺, calcd 1046.5507); ¹H NMR (CDCl₃) δ 9.40 (br s, 1H, ex, NH(U)), 7.97 (s, 1H, H6), 7.22–7.49 (m, 9H, Ar), 6.87 (d, 4H, *J* = 9.0 Hz, Ar), 5.58 (s, 1H, H1'), 5.34 (d, 1H, *J* = 5.0 Hz, HC=C-chol), 4.96 (bs, 1H, ex, NHCH₂), 4.53 (s, 1H, H2'), 4.40–4.47 (m, 1H, HC-O-chol), 4.23 (bs, 1H, H3'), 3.83–3.98 (m, 4H, 2 × H5'', CH₂NH), 3.80 (s, 3H, CH₃O), 3.79 (s, 6H, 2 × CH₃O), 3.58–3.61 (d, 1H, *J* = 11.0 Hz, H5'), 3.51–3.53 (d, 1H, *J* = 11.0 Hz, H5'), 3.27 (bs, 1H, ex, 3'-OH), 0.87–2.29 (m, 40 H, chol), 0.69 (s, 3H, CH₃-chol); ¹³C NMR (CDCl₃) δ 162.1, 158.63, 158.60, 155.5, 148.7, 144.5, 141.8 (C6), 139.8, 135.44, 135.39, 130.0 (Ar), 128.1 (Ar), 128.0 (Ar), 127.0 (Ar), 122.5 (=CH, chol), 113.4 (Ar), 99.2, 90.1, 88.4, 87.4 (C1'), 86.6, 79.1 (C2'), 74.7 (OCH-chol), 74.1, 71.9 (C5''), 70.6 (C3'), 58.6 (C5'), 56.7 (CH-chol), 56.2 (CH-chol), 55.2 (CH₃O), 50.0 (CH-chol), 42.3, 39.8 (CH₂-chol), 39.5 (CH₂-chol), 38.5 (CH₂-chol), 37.0 (CH₂-chol), 36.5, 36.2 (CH₂-chol), 35.8 (CH-chol), 31.9 (CH-chol/CH₂NH), 28.2 (CH₂-chol), 28.1 (CH₂-chol), 28.0 (CH-chol), 24.3 (CH₂-chol), 23.8 (CH₂-chol), 22.8 (CH₃-chol), 22.5 (CH₃-chol), 21.0 (CH₂-chol), 19.3 (CH₃-chol), 18.7 (CH₃-chol), 11.8 (CH₃-chol). Signals at 41.4, 29.0, 22.6, 20.4, 19.4, 14.3, and 11.4 ppm, presumably arising from a small contamination of unreacted cholesterylprop-2-ynylcarbamate, were also observed in the ¹³C NMR spectrum.

(1*R*,3*R*,4*R*,7*S*)-1-(4,4'-Dimethoxytrityloxymethyl)-7-hydroxy-3-[5-(2-(1-pyrenyl)ethynyl)uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (**4i**). Nucleoside **3** (0.34 g, 0.50 mmol), Pd(PPh₃)₄ (60 mg, 0.05 mmol), CuI (20 mg, 0.10 mmol), 1-ethynylpyrene⁵⁰ (0.28 g, 1.00 mmol), and Et₃N (0.30 mL, 2.84 mmol) in DMF (10 mL) were reacted as described in the representative Sonogashira protocol, and the mixture was stirred at room temperature for 12 h. Following workup and purification, nucleoside **4i** (0.31 g, 80%) was obtained as a

slightly yellow solid, which was used in the next step without further purification: $R_f = 0.5$ (5% MeOH in CH_2Cl_2 , v/v); MALDI-HRMS m/z 805.2554 ($[\text{M} + \text{Na}]^+$, $\text{C}_{49}\text{H}_{38}\text{N}_2\text{O}_8\text{Na}^+$, calcd 805.2520); ^1H NMR (DMSO- d_6) δ 11.89 (s, 1H, ex, NH), 8.35 (d, 1H, $J = 8.5$ Hz, Ar), 8.31–8.34 (d, 1H, $J = 8.5$ Hz, Ar), 8.25–8.28 (d, 1H, $J = 8.0$ Hz, Ar), 8.14–8.23 (m, 4H, H6, Ar), 8.09–8.12 (ap t, 1H, $J = 8.0$ Hz, Ar), 7.93 (d, 1H, $J = 8.5$ Hz, Ar), 7.67 (d, 1H, $J = 8.0$ Hz, Ar), 7.49–7.50 (m, 2H, Ar), 7.33–7.38 (m, 4H, Ar), 7.26–7.30 (ap t, 2H, $J = 7.5$ Hz, Ar), 7.03–7.06 (ap t, 1H, $J = 7.5$ Hz, Ar), 6.78–6.85 (m, 4H, Ar), 5.78 (d, 1H, ex, $J = 4.5$ Hz, 3'-OH), 5.53 (s, 1H, H1'), 4.34 (s, 1H, H2'), 4.24 (d, 1H, $J = 4.5$ Hz, H3'), 3.78–3.82 (2d, 2H, $J = 7.5$ Hz, H5''), 3.43–3.52 (m, 7H, OCH₃, H5'), 3.38–3.42 (d, 1H, $J = 11.0$ Hz, H5''); ^{13}C NMR (DMSO- d_6) δ 161.7, 158.02, 157.95, 149.1, 144.4, 141.4 (C6), 135.4, 130.8, 130.7, 130.6, 130.4, 129.6 (Ar), 129.5 (Ar), 128.8 (Ar), 128.2 (Ar), 128.1 (Ar), 127.8 (Ar), 127.7 (Ar), 127.1 (Ar), 126.63 (Ar), 126.58 (Ar), 125.7 (Ar), 125.6 (Ar), 124.8 (Ar), 124.5 (Ar), 123.5, 123.3, 116.9, 113.17 (Ar), 113.16 (Ar), 98.2, 91.3, 88.2, 87.8, 87.2 (C1'), 85.6, 78.8 (C2'), 71.4 (C5''), 69.4 (C3'), 58.7 (C5'), 54.7 (OCH₃), 54.6 (OCH₃). A trace of pyridine was observed in the ^{13}C NMR.⁴⁸

(1*R*,3*R*,4*R*,7*S*)-1-(4,4'-Dimethoxytrityloxymethyl)-7-hydroxy-3-[5-(2-(3-phenyl)ethynyl)uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (4j). Nucleoside 3 (0.50 g, 0.73 mmol), Pd(PPh₃)₄ (90 mg, 0.07 mmol), CuI (30 mg, 0.14 mmol), 3-ethynylperylene⁵¹ (0.27 g, 1.00 mmol), and Et₃N (0.40 mmol, 2.84 mmol) in DMF (10 mL) were reacted as described in the representative Sonogashira protocol, and the mixture was stirred at room temperature for 12 h. After workup and purification, nucleoside 4j (0.49 g, 80%) was obtained as a brown solid material: $R_f = 0.5$ (5% MeOH in CH_2Cl_2 , v/v); MALDI-HRMS m/z 855.2675 ($[\text{M} + \text{Na}]^+$, $\text{C}_{53}\text{H}_{40}\text{N}_5\text{O}_8\text{Na}^+$, calcd 855.2677); ^1H NMR (DMSO- d_6) δ 11.86 (s, 1H, ex, NH), 8.34–8.40 (m, 3H, Ar), 8.22 (d, 1H, $J = 8.0$ Hz, Ar), 8.13 (s, 1H, H6), 8.02 (d, 1H, $J = 8.5$ Hz, Ar), 7.79–7.85 (m, 2H, Ar), 7.55 (dt, 2H, $J = 8.0$ Hz, 2.0 Hz, Ar), 7.48–7.51 (m, 2H, Ar), 7.28–7.37 (m, 7H, Ar), 7.22 (d, 1H, $J = 8.0$ Hz, Ar), 7.09–7.12 (t, 1H, $J = 7.5$ Hz, Ar), 6.83–6.88 (m, 4H, Ar), 5.77 (d, 1H, ex, $J = 4.5$ Hz, 3'-OH), 5.51 (s, 1H, H1'), 4.33 (s, 1H, H2'), 4.22 (d, 1H, $J = 4.5$ Hz, H3'), 3.77–3.83 (m, 2H, 2 × H5''), 3.59 (s, 3H, OCH₃), 3.56 (s, 3H, OCH₃), 3.48–3.51 (d, 1H, $J = 11.0$ Hz, H5'), 3.35–3.39 (d, 1H, $J = 11.0$ Hz, H5''); ^{13}C NMR (DMSO- d_6) δ 161.7, 158.05, 158.00, 149.0, 144.4, 141.3 (C6), 135.43, 135.37, 134.2, 133.6, 130.9, 130.7, 130.4 (Ar), 130.1, 129.9, 129.6 (Ar), 129.5 (Ar), 128.5 (Ar), 128.2 (Ar), 127.9 (Ar), 127.7 (Ar), 127.60, 127.57, 127.47 (Ar), 127.0 (Ar), 126.9 (Ar), 126.7 (Ar), 125.7 (Ar), 121.5 (Ar), 121.2, 121.1 (Ar), 120.0 (Ar), 119.4, 113.2 (Ar), 98.1, 90.9, 88.5, 87.7, 87.1 (C1'), 85.6, 78.8 (C2'), 71.4 (C5''), 69.4 (C3'), 58.7 (C5'), 54.80 (CH₃O), 54.75 (CH₃O).

(1*R*,3*R*,4*R*,7*S*)-1-(4,4'-Dimethoxytrityloxymethyl)-7-hydroxy-3-[5-(1-(1-pyrenyl)-1*H*-1,2,3-triazol-4-yl)-uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (4k). To a solution of nucleoside 4b (0.25 g, 0.36 mmol) and 1-pyrenyl azide²⁶ (110 mg, 0.45 mmol) in THF/H₂O/*t*-BuOH (10 mL, 3/1/1, v/v/v) were added aqueous sodium ascorbate (1 M, 0.70 mL, 0.70 mmol) and aqueous CuSO₄ (7.5%, w/v, 0.65 mL, 0.19 mmol). The solution was stirred at room temperature for 2 h, whereupon it was taken up in EtOAc (50 mL) and brine (50 mL). The layers were separated, and the organic phase was washed with saturated aqueous NaHCO₃ (50 mL). The combined aqueous phase was back-extracted with EtOAc (50 mL). The combined organic phase was then dried (Na₂SO₄) and evaporated to dryness and the resulting residue purified by column chromatography (0–75% EtOAc in petroleum ether, v/v) to afford nucleoside 4k (230 mg, 76%) as a slightly yellow solid material: $R_f = 0.4$ (70% EtOAc in petroleum ether, v/v); ESI-HRMS m/z 848.2712 ($[\text{M} + \text{Na}]^+$, $\text{C}_{49}\text{H}_{39}\text{N}_5\text{O}_8\text{Na}^+$, calcd 848.2691); ^1H NMR (DMSO- d_6) δ 11.85 (s, 1H, ex, NH), 8.84 (s, 1H, H-Tz), 8.58 (s, 1H, H6), 8.48 (d, 1H, $J = 8.0$ Hz, Ar), 8.44–8.47 (d, 1H, $J = 7.5$ Hz, Ar), 8.40–8.43 (d, 1H, $J = 8.0$ Hz, Ar), 8.35–8.38 (d, 1H, $J = 9.0$ Hz, Ar), 8.32–8.35 (d, 1H, $J = 9.0$ Hz, Ar), 8.30 (d, 1H, $J = 9.0$ Hz, Ar), 8.16–8.20 (overlapping d and t, 2H, Ar), 7.79 (d, 1H, $J = 8.0$ Hz, Ar), 7.45–7.48 (d, 2H, $J = 7.5$ Hz, Ar), 7.28–7.39 (m, 6H, Ar), 7.17–7.20 (t, 1H, $J = 7.5$ Hz, Ar), 6.88–6.93 (2d, 4H, $J = 9.0$ Hz, Ar), 5.79 (d, 1H, ex, $J = 4.5$ Hz, 3'-OH), 5.64

(s, 1H, H1'), 4.43 (s, 1H, H2'), 4.13 (d, 1H, $J = 4.5$ Hz, H3'), 3.94–3.97 (d, 1H, $J = 9.0$ Hz, H5''), 3.86–3.90 (d, 1H, $J = 9.0$ Hz, H5''), 3.681 (s, 3H, CH₃O), 3.675 (s, 3H, CH₃O), 3.57–3.60 (d, 1H, $J = 11.0$ Hz, H5'), 3.34–3.37 (m, 1H, $J = 11.0$ Hz, H5''); ^{13}C NMR (DMSO- d_6) δ 161.3, 158.05, 158.02, 149.4, 144.6, 139.4, 135.3, 135.2, 135.0 (C6), 131.6, 130.6, 130.14, 130.09, 129.7 (Ar), 129.6 (Ar), 129.5 (Ar), 128.7 (Ar), 127.8 (Ar), 127.6 (Ar), 127.0 (Ar), 126.6 (Ar), 126.5 (Ar), 126.1 (Ar), 125.3, 125.1 (Ar), 124.8 (CH-Tz), 124.0, 123.7 (Ar), 123.3, 120.9 (Ar), 113.24 (Ar), 113.19 (Ar), 104.3, 87.6, 87.2 (C1'), 85.6, 79.0 (C2'), 71.5 (C5''), 70.0 (C3'), 59.5 (C5'), 54.9 (CH₃O).

(1*R*,3*R*,4*R*,7*S*)-1-(4,4'-Dimethoxytrityloxymethyl)-7-hydroxy-3-[5-(1-(1-pyrenyl)-1*H*-1,2,3-triazol-4-yl)-uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (4l). To a solution of nucleoside 4b (0.33 g, 0.56 mmol) and 1-azidomethylpyrene²⁷ (200 mg, 0.78 mmol) in THF/H₂O/*t*-BuOH (10 mL, 3/1/1, v/v/v) were added aqueous sodium ascorbate (1 M, 1.00 mL, 1.00 mmol) and aqueous CuSO₄ (7.5%, w/v, 1.00 mL, 0.30 mmol). The reaction mixture was stirred at room temperature for 2 h, whereupon it was taken up in EtOAc (50 mL) and brine (50 mL). The layers were separated, and the organic phase was washed with saturated aqueous NaHCO₃ (50 mL). The combined aqueous phase was back-extracted with EtOAc (50 mL). The combined organic phase was dried (Na₂SO₄) and evaporated to dryness and the resulting residue purified by column chromatography (0–75% EtOAc in petroleum ether, v/v) to afford nucleoside 4l (0.43 g, 91%) as a slightly yellow solid material: $R_f = 0.4$ (70% EtOAc in petroleum ether, v/v); ESI-HRMS m/z 862.2869 ($[\text{M} + \text{Na}]^+$, $\text{C}_{50}\text{H}_{41}\text{N}_5\text{O}_8\text{Na}^+$, calcd 862.2847); ^1H NMR (DMSO- d_6) δ 11.70 (s, 1H, ex, NH), 8.56 (d, 1H, $J = 9.0$ Hz, Ar), 8.44 (s, 1H, H-Tz), 8.29–8.36 (m, 5H, H6, Ar), 8.20–8.23 (d, 1H, $J = 9.0$ Hz, Ar), 8.17–8.20 (d, 1H, $J = 9.0$ Hz, Ar), 8.09–8.12 (t, 1H, $J = 8.0$ Hz, Ar), 8.07 (d, 1H, $J = 8.0$ Hz, Ar), 7.39–7.42 (d, 2H, $J = 7.5$ Hz, Ar), 7.22–7.33 (m, 6H, Ar), 7.09–7.12 (t, 1H, $J = 7.5$ Hz, Ar), 6.88 (d, 4H, $J = 8.0$ Hz, Ar), 6.40 (s, 2H, CH₂Py), 5.69 (d, 1H, ex, $J = 4.5$ Hz, 3'-OH), 5.55 (s, 1H, H1'), 4.32 (s, 1H, H2'), 3.91–3.96 (m, 2H, H3', H5''), 3.81–3.84 (d, 1H, $J = 8.0$ Hz, H5''), 3.70 (s, 3H, CH₃O), 3.68 (s, 3H, CH₃O), 3.50–3.54 (d, 1H, $J = 11.0$ Hz, H5'), 3.25–3.29 (d, 1H, $J = 11.0$ Hz, H5''); ^{13}C NMR (DMSO- d_6) δ 161.2, 158.1, 158.0, 149.2, 144.7, 138.9, 135.1, 134.2 (C6), 131.0, 130.7, 130.1, 129.7 (Ar), 129.6 (Ar), 129.1, 128.4, 128.2 (Ar), 127.8 (Ar), 127.6 (Ar), 127.5 (Ar), 127.2 (Ar), 126.52 (Ar), 126.45 (Ar), 125.7 (Ar), 125.5 (Ar), 125.0 (Ar), 124.0, 123.7, 122.7 (Ar), 122.4 (CH-Tz), 113.3 (Ar), 113.2 (Ar), 104.5, 87.5, 87.1 (C1'), 85.6, 79.0 (C2'), 71.6 (C5''), 70.0 (C3'), 59.8 (C5'), 54.9 (CH₃O), 54.8 (CH₃O), 50.7 (CH₂Py).

Representative Procedure for O3'-Phosphitylation. Alcohols 5b–l were dried by coevaporation with anhydrous 1,2-dichloroethane and dissolved in anhydrous CH₂Cl₂. To this were added anhydrous *N,N'*-diisopropylethylamine (DIPEA) and 2-cyanoethyl-*N,N'*-diisopropylchlorophosphoramidite (PCI-reagent) (quantities and volumes specified below), and the reaction mixture was stirred at room temperature until analytical TLC indicated complete conversion (2 h unless otherwise mentioned). Unless otherwise mentioned, the reaction mixture was diluted with CH₂Cl₂ (25 mL) and washed with aqueous NaHCO₃ (2 × 10 mL), the combined aqueous phases were back-extracted with CH₂Cl₂ (2 × 10 mL), and the combined organic phases were dried (Na₂SO₄) and evaporated to dryness. Regardless of the workup procedure, the resulting residue was purified by silica gel column chromatography (typically 0–4% MeOH/CH₂Cl₂, v/v) and subsequent trituration from CH₂Cl₂ and petroleum ether to provide the target phosphoramidites.

(1*R*,3*R*,4*R*,7*S*)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoyl]-1-(4,4'-dimethoxytrityloxymethyl)-3-(5-ethynyluracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (5b). Nucleoside 4b (0.34 g, 0.58 mmol), DIPEA (0.50 mL, 2.90 mmol), PCI-reagent (0.20 mL, 0.87 mmol), and anhydrous CH₂Cl₂ (10 mL) were mixed, reacted, worked up, and purified as described in the representative protocol to provide nucleoside 5b (0.38 g, 83%) as a white foam: $R_f = 0.5$ (2% MeOH in CH₂Cl₂, v/v); ESI-HRMS m/z 805.2973 ($[\text{M} + \text{Na}]^+$, $\text{C}_{42}\text{H}_{47}\text{N}_4\text{O}_9\text{PNa}^+$, calcd 805.2958); ^{31}P NMR (CDCl₃) δ 149.8, 149.3.

(1*R*,3*R*,4*R*,7*S*)-3-[5-(3-Benzoyloxypropyn-1-yl)uracil-1-yl]-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-2,5-dioxabicyclo[2.2.1]heptane (**5c**). Nucleoside **4c** (0.30 g, 0.42 mmol), DIPEA (300 μ L, 1.67 mmol), PCl-reagent (121 μ L, 0.54 mmol), and anhydrous CH₂Cl₂ (5 mL) were mixed and reacted (5 h) as described above. At this point the reaction mixture was concentrated to one-third volume and diluted with diethyl ether (100 mL) and the organic phase sequentially washed with H₂O (35 mL), H₂O/DMF (70 mL, 1/1, v/v), H₂O (35 mL), and brine (35 mL). The organic phase was evaporated to dryness and the resulting residue purified as described in the representative protocol to provide nucleoside **5c** (150 mg, 43%) as a white foam: $R_f = 0.6$ (5% MeOH in CH₂Cl₂, v/v); ESI-HRMS m/z 939.3356 ([M + Na]⁺, C₅₀H₅₃N₄O₁₁P·Na⁺, calcd 939.3341); ³¹P NMR (CDCl₃) δ 149.8, 149.3.

(1*R*,3*R*,4*R*,7*S*)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-3-[5-(3-trifluoroacetylaminopropyn-1-yl)uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (**5d**). Nucleoside **4d** (0.37 g, 0.52 mmol), DIPEA (0.44 mL, 2.52 mmol), PCl-reagent (0.18 mL, 0.78 mmol), and anhydrous CH₂Cl₂ (10 mL) were mixed, reacted, worked up, and purified as described in the representative protocol to provide nucleoside **5d** (0.39 g, 80%) as a white foam: $R_f = 0.5$ (2% MeOH in CH₂Cl₂, v/v); ESI-HRMS m/z 930.3068 ([M + Na]⁺, C₄₅H₄₉F₃N₅O₁₀P·Na⁺, calcd 930.3061); ³¹P NMR (CDCl₃) δ 149.7, 149.1.

(1*R*,3*R*,4*R*,7*S*)-3-[5-(3-(1-Adamantylmethylcarbonyl)aminopropyn-1-yl)uracil-1-yl]-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-2,5-dioxabicyclo[2.2.1]heptane (**5e**). Nucleoside **4e** (204 mg, 0.26 mmol), DIPEA (184 μ L, 1.06 mmol), and PCl-reagent (106 μ L, 0.48 mmol) in anhydrous CH₂Cl₂ (4 mL) were mixed and reacted as described in the representative protocol. At this point, ice-cold EtOH (1 mL) was added and the solvents were evaporated off. Purification as described in the representative protocol provided nucleoside **4e** (190 mg, 74%) as a slightly yellow foam: $R_f = 0.4$ (5% MeOH in CH₂Cl₂, v/v); MALDI-HRMS m/z 1010.4408 ([M + Na]⁺, C₅₅H₆₆N₅O₁₀P·Na⁺, calcd 1010.4440); ³¹P NMR (CDCl₃) δ 149.8, 149.2. A minor impurity at ~14 ppm was observed.

(1*R*,3*R*,4*R*,7*S*)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-3-[5-(3-dodecanoylamino)propyn-1-yl]uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (**5f**). Nucleoside **4f** (175 mg, 0.22 mmol), DIPEA (154 μ L, 0.88 mmol), *N*-methylimidazole (14 μ L, 0.18 mmol), PCl-reagent (75 μ L, 0.33 mmol), and anhydrous CH₂Cl₂ (3 mL) were mixed and reacted (2.5 h). The solvents were evaporated off, and the resulting residue was purified as described in the representative protocol to provide nucleoside **5f** (183 mg, 83%) as a white foam: $R_f = 0.4$ (4% MeOH in CH₂Cl₂, v/v); MALDI-HRMS m/z 1016.4983 ([M + Na]⁺, C₅₅H₇₂N₅O₁₀P·Na⁺, calcd 1016.4909); ³¹P NMR (CDCl₃) δ 149.8, 149.2.

(1*R*,3*R*,4*R*,7*S*)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-3-[5-(3-octadecanoylamino)propyn-1-yl]uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (**5g**). Nucleoside **4g** (0.25 g, 0.28 mmol), DIPEA (0.24 mL, 1.37 mmol), PCl-reagent 0.10 mL, 0.42 mmol), and anhydrous CH₂Cl₂ (10 mL) were mixed, reacted, worked up, and purified as described in the representative protocol to provide nucleoside **5g** (180 mg, 60%) as a white foam: $R_f = 0.5$ (2% MeOH in CH₂Cl₂, v/v); ESI-HRMS m/z 1100.5836 ([M + Na]⁺, C₆₁H₈₄N₅O₁₀P·Na⁺, calcd 1100.5848); ³¹P NMR (CDCl₃) δ 149.8, 149.2.

(1*R*,3*R*,4*R*,7*S*)-3-[5-(3-Cholesterylcarbonylaminopropyn-1-yl)uracil-1-yl]-7-[2-cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-2,5-dioxabicyclo[2.2.1]heptane (**5h**). Nucleoside **4h** (240 mg, 0.23 mmol), DIPEA (0.19 mL, 1.08 mmol), PCl-reagent (0.08 mL, 0.34 mmol), and anhydrous CH₂Cl₂ (10 mL) were mixed, reacted, worked up, and purified as described in the representative protocol to provide nucleoside **5h** (190 mg, 66%) as a white foam: $R_f = 0.5$ (2% MeOH in CH₂Cl₂, v/v); ESI-HRMS m/z 1246.6571 ([M + Na]⁺, C₇₁H₉₄N₅O₁₁P·Na⁺, calcd 1246.6579); ³¹P NMR (CDCl₃) δ 149.8, 149.3.

(1*R*,3*R*,4*R*,7*S*)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-3-[5-(2-(1-pyrenyl)ethynyl)-

uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (**5i**). Nucleoside **4i** (0.20 g, 0.26 mmol), DIPEA (225 μ L, 1.28 mmol), PCl-reagent (114 μ L, 0.51 mmol), and anhydrous CH₂Cl₂ (4 mL) were mixed and reacted (4.5 h) as described in the representative protocol. Solvents were evaporated off, and the resulting residue was purified as described in the representative protocol to provide nucleoside **5i** (188 mg, 75%) as a pale yellow foam: $R_f = 0.5$ (5% MeOH in CH₂Cl₂, v/v); MALDI-HRMS m/z 1005.3661 ([M + Na]⁺, C₅₈H₅₅N₄O₉P·Na⁺, calcd 1005.3606); ³¹P NMR (CDCl₃) δ 149.7, 149.3.

(1*R*,3*R*,4*R*,7*S*)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-3-[5-(2-(3-phenylethynyl)uracil-1-yl)-2,5-dioxabicyclo[2.2.1]heptane (**5j**). Nucleoside **4j** (0.47 g, 0.56 mmol), DIPEA (0.40 mL, 2.26 mmol), PCl-reagent (165 μ L, 0.73 mmol), and anhydrous CH₂Cl₂ (4 mL) were mixed, reacted (3 h), worked up, and purified as described in the representative protocol to provide nucleoside **5j** (0.43 g, 78%) as a yellow foam: $R_f = 0.4$ (4% MeOH in CH₂Cl₂, v/v); ESI-HRMS m/z 1055.3751 ([M + Na]⁺, C₆₂H₅₇N₄O₉P·Na⁺, calcd 1055.3763); ³¹P NMR (CDCl₃) δ 149.7, 149.3.

(1*R*,3*R*,4*R*,7*S*)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-3-[5-(1-(1-pyrenyl)-1*H*-1,2,3-triazol-4-yl)uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (**5k**). Nucleoside **4k** (180 mg, 0.22 mmol), DIPEA (160 μ L, 0.88 mmol), PCl-reagent (63 μ L, 0.28 mmol), and anhydrous CH₂Cl₂ (1.5 mL) were mixed and reacted (2.5 h) as described in the representative protocol. At this point, the reaction mixture was diluted with EtOAc (20 mL) and washed with H₂O (2 \times 25 mL). The organic phase was dried (Na₂SO₄) and evaporated to dryness and the resulting residue purified as described in the representative protocol to provide nucleoside **5k** (184 mg, 82%) as a white foam: $R_f = 0.7$ (5% MeOH in CH₂Cl₂, v/v); ESI-HRMS m/z 1048.3789 ([M + Na]⁺, C₅₈H₅₆N₇O₉P·Na⁺, calcd 1048.3769); ³¹P NMR (CDCl₃) δ 149.8, 149.1.

(1*R*,3*R*,4*R*,7*S*)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-(4,4'-dimethoxytrityloxymethyl)-3-[5-(1-(pyren-1-ylmethyl)-1*H*-1,2,3-triazol-4-yl)uracil-1-yl]-2,5-dioxabicyclo[2.2.1]heptane (**5l**). Nucleoside **4l** (0.41 g, 0.49 mmol), DIPEA (345 μ L, 1.95 mmol), PCl-reagent (165 μ L, 0.73 mmol), and anhydrous CH₂Cl₂ (5 mL) were mixed, reacted (2.5 h), worked up, and purified as described in the representative protocol to provide nucleoside **5l** (190 mg, 40%) as a white foam: $R_f = 0.5$ (3% MeOH in CH₂Cl₂, v/v); ESI-HRMS m/z 1062.3909 ([M + Na]⁺, C₅₉H₅₈N₇O₉P·Na⁺, calcd 1062.3934); ³¹P NMR (CDCl₃) δ 149.6, 149.1.

Synthesis and Purification of ONs. L1–4, K1–4, N1–4, Q1–4, S1–4, and VS were prepared and characterized with respect to identity (MALDI-MS) and purity (>80%, ion-pair reverse-phase HPLC) in previous studies.^{22,37} All of the other ONs were synthesized, worked up, purified, and characterized essentially as previously described.³⁷ Briefly, ONs were synthesized on a 0.2 μ mol scale using an automated DNA synthesizer and long chain alkyl amine controlled pore glass columns with a pore size of 500 Å. Standard reagents were used. The following hand-coupling conditions were employed to incorporate monomers K–Z into ONs, which generally resulted in coupling yields in excess of 95% (coupling time; activator; phosphoramidite solvent): monomers K/L/M/N/O/Q/S/W/Z (15 min; 0.25 M 4,5-dicyanoimidazole in CH₃CN; CH₃CN), monomer P (15 min; 0.25 M 4,5-dicyanoimidazole in CH₃CN; CH₂Cl₂), monomer V (30 min; 0.25 M 4,5-dicyanoimidazole in CH₃CN; CH₂Cl₂), and monomers X/Y/Z (15 min; 0.25 M 5-[3,5-bis(trifluoromethyl)phenyl]-1*H*-tetrazole⁵² in CH₃CN; CH₂Cl₂). ONs were cleaved from the solid support and protecting groups removed through treatment with concentrated aqueous ammonia (55 °C, 24 h). ONs were purified by ion-pair reverse-phase HPLC (XTerra MS C18 column) using a gradient of 0.05 M triethylammonium acetate in water and 25% water in CH₃CN, followed by detritylation (80% aqueous AcOH) and precipitation (NaOAc/NaClO₄/acetone, –18 °C for 12–16 h). The identity of all synthesized ONs was verified by MALDI MS analysis (Table S1, Supporting Information) recorded in positive ion mode on a quadrupole time-of-flight tandem mass spectrometer equipped with

a MALDI source. Purity (>80%) was verified by ion-pair reverse-phase HPLC running in analytical mode.

Biophysical Characterization Studies. Thermal denaturation temperatures and steady-state fluorescence emission spectra were determined essentially as previously described.³⁷ Briefly, thermal denaturation temperatures were determined as the maximum of the first derivative of the thermal denaturation curve (A_{260} vs T) recorded in medium salt buffer (T_m buffer: 110 mM NaCl, 0.1 mM EDTA, pH adjusted with 10 mM $\text{Na}_2\text{HPO}_4/\text{NaH}_2\text{PO}_4$). A temperature ramp of 0.5 °C/min was used in all experiments. Reported thermal denaturation temperatures are an average of at least two experiments within ± 1.0 °C.

Thermodynamic parameters for duplex formation were determined through baseline fitting of denaturation curves (van't Hoff analysis) using software provided with the UV/vis spectrometer. Bimolecular reactions, two-state melting behavior, and a heat capacity change of $\Delta C_p = 0$ upon hybridization were assumed. A minimum of two experimental denaturation curves were each analyzed to minimize errors arising from baseline choice. Averages are listed.

3'-Exonuclease degradation studies were performed by observing the change in absorbance at 260 nm and 37 °C as a function of time for a solution of ONs (3.3 μM) in magnesium buffer (600 μL , 50 mM Tris-HCl, 10 mM MgCl_2 , pH 9.0) to which SVPDE (snake venom phosphodiesterase) dissolved in H_2O was added (12 μL , 0.52 μg , 0.03 U).

Steady-state fluorescence emission spectra were recorded using the same buffers and ON concentrations (1.0 μM) as in thermal denaturation studies. Fluorescence emission spectra were recorded at 5 °C to ensure maximum hybridization. Deoxygenation was deliberately not applied to the samples, since the scope of the work was to determine fluorescence under aerated conditions prevailing in bioassays. Steady-state fluorescence emission spectra were obtained as an average of five scans using λ_{ex} 344 nm for V/Y/Z-modified ONs, λ_{ex} 375 nm for W-modified ONs, λ_{ex} 448 nm for X-modified ONs, excitation slit 5.0 nm, emission slit 5.0 nm, and a scan speed of 600 nm/min.

■ ASSOCIATED CONTENT

■ Supporting Information

Text, tables, and figures giving general experimental details, NMR spectra for all new compounds, MS data for all new modified ONs, additional T_m data, 3'-exonuclease degradation and fluorescence data, and structures of modified DNA monomers. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail for P.J.H.: hrdlicka@uidaho.edu.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We appreciate financial support from the Idaho NSF EPSCoR, the BANTech Center at the University of Idaho, and Award No. GM088697 from the National Institute of General Medical Sciences, National Institutes of Health. Scholarships from the College of Graduate Studies (M.E.Ø.) and the National Science Foundation under Award No. 0648202 and the Department of Defense ASSURE (Awards to Stimulate and Support Undergraduate Research Experiences) Program (D.J.R.) are appreciated. We thank Dr. Alexander Blumenfeld (Department of Chemistry), Dr. Gary Knerr (Department of Chemistry) and Dr. Lee Deobald (EBI Murdock Mass Spectrometry Center, University of Idaho) for NMR and mass spectrometric analyses.

Preliminary synthetic efforts by T. Santhosh Kumar (University of Southern Denmark) are appreciated.

■ REFERENCES

- (1) For recent reviews on conformationally restricted nucleotides, see e.g.: (a) Herdewijn, P. *Chem. Biodiv.* **2010**, *7*, 1–59. (b) Obika, S.; Abdur Rahman, S. M.; Fujisaka, A.; Kawada, Y.; Baba, T.; Imanishi, T. *Heterocycles* **2010**, *81*, 1347–1392. (c) Prakash, T. P. *Chem. Biodiv.* **2011**, *8*, 1616–1641. (d) Zhou, C.; Chattopadhyaya, J. *Chem. Rev.* **2012**, *112*, 3808–3832.
- (2) For recent representative examples, see: (a) Seth, P. P.; Vasquez, G.; Allerson, C. A.; Berdeja, A.; Gaus, H.; Kinberger, G. A.; Prakash, T. P.; Migawa, M. T.; Bhat, B.; Swayze, E. E. *J. Org. Chem.* **2010**, *75*, 1569–1581. (b) Li, Q.; Yuan, F.; Zhou, C.; Plashkevych, O.; Chattopadhyaya, J. *J. Org. Chem.* **2010**, *75*, 6122–6140. (c) Liu, Y.; Xu, J.; Karimiahmadabadi, M.; Zhou, C.; Chattopadhyaya, J. *J. Org. Chem.* **2010**, *75*, 7112–7128. (d) Upadhyaya, R.; Deshpande, S. A.; Li, Q.; Kardile, R. A.; Sayyed, A. Y.; Kshirsagar, E. K.; Salunke, R. V.; Dixit, S. S.; Zhou, C.; Foldesi, A.; Chattopadhyaya, J. *J. Org. Chem.* **2011**, *76*, 4408–4431. (e) Shrestha, A. R.; Hari, Y.; Yahara, A.; Osawa, T.; Obika, S. *J. Org. Chem.* **2011**, *76*, 9891–9899. (f) Hanessian, S.; Schroeder, B. R.; Giacometti, R. D.; Merner, B. L.; Østergaard, M. E.; Swayze, E. E.; Seth, P. P. *Angew. Chem., Int. Ed.* **2012**, *51*, 11242–11245. (g) Madsen, A. S.; Wengel, J. *J. Org. Chem.* **2012**, *77*, 3878–3886. (h) Haziri, A. I.; Leumann, C. J. *J. Org. Chem.* **2012**, *77*, 5861–5869. (i) Gerber, A.-B.; Leumann, C. J. *Chem. Eur. J.* **2013**, *19*, 6990–7006. (j) Morihoro, K.; Kodama, T.; Kentefu; Moai, Y.; Veedu, R. N.; Obika, S. *Angew. Chem., Int. Ed.* **2013**, *52*, 5074–5078. (k) Hari, Y.; Osawa, T.; Kotobuki, Y.; Yahara, A.; Shrestha, A. R.; Obika, S. *Bioorg. Med. Chem.* **2013**, *21*, 4405–4412. (l) Hari, Y.; Morikawa, T.; Osawa, T.; Obika, S. *Org. Lett.* **2013**, *15*, 3702–3705. (m) Migawa, M. T.; Prakash, T. P.; Vasquez, G.; Seth, P. P.; Swayze, E. E. *Org. Lett.* **2013**, *15*, 4316–4319. (n) Hanessian, S.; Schroeder, B. R.; Merner, B. L.; Chen, B.; Swayze, E. E.; Seth, P. P. *J. Org. Chem.* **2013**, *78*, 9051–9063. (o) Hanessian, S.; Waggar, J.; Merner, B. L.; Giacometti, R. D.; Østergaard, M. E.; Swayze, E. E.; Seth, P. P. *J. Org. Chem.* **2013**, *78*, 9064–9075.
- (3) Eschenmoser, A. *Science* **1999**, *284*, 2118–2124.
- (4) Hendrix, C.; Rosemeyer, H.; Verheggen, I.; Van Aerschot, A.; Seela, F.; Herdewijn, P. *Chem. Eur. J.* **1997**, *3*, 110–120.
- (5) Wang, J.; Verbeure, B.; Luyten, I.; Lescrinier, E.; Froeyen, M.; Hendrix, C.; Rosemeyer, H.; Seela, F.; Van Aerschot, A.; Herdewijn, P. *J. Am. Chem. Soc.* **2000**, *122*, 8595–8602.
- (6) Bolli, M.; Trafelet, H. U.; Leumann, C. *Nucleic Acids Res.* **1996**, *24*, 4660–4667.
- (7) Renneberg, D.; Leumann, C. J. *J. Am. Chem. Soc.* **2002**, *124*, 5993–6002.
- (8) Singh, S. K.; Nielsen, P.; Koshkin, A. A.; Wengel, J. *Chem. Commun.* **1998**, 455–456.
- (9) Kaur, H.; Babu, B. R.; Maiti, S. *Chem. Rev.* **2007**, *107*, 4672–4697.
- (10) Obika, S.; Nanbu, D.; Hari, Y.; Andoh, J.-I.; Morio, K.-I.; Doi, T.; Imanishi, T. *Tetrahedron Lett.* **1998**, *39*, 5401–5404.
- (11) Kool, E. T. *Chem. Rev.* **1997**, *97*, 1473–1487.
- (12) (a) Duca, M.; Vekhoff, P.; Oussedik, K.; Halby, L.; Arimondo, P. B. *Nucleic Acids Res.* **2008**, *36*, 5123–5138. (b) Bennett, C. F.; Swayze, E. E. *Annu. Rev. Pharmacol. Toxicol.* **2010**, *50*, 259–293. (c) Østergaard, M. E.; Hrdlicka, P. J. *Chem. Soc. Rev.* **2011**, *40*, 5771–5788. (d) Watts, J. K.; Corey, D. R. *J. Pathol.* **2012**, *226*, 365–379. (e) Matsui, M.; Corey, D. R. *Drug Discuss. Today* **2012**, *17*, 443–450. (f) Dong, H.; Lei, J.; Ding, L.; Wen, Y.; Ju, H.; Zhang, X. *Chem. Rev.* **2013**, *113*, 6207–6233.
- (13) (a) Wahlestedt, C.; Salmi, P.; Good, L.; Kela, J.; Johnsson, T.; Hokfelt, T.; Broberger, C.; Porreca, F.; Lai, J.; Ren, K. K.; Ossipov, M.; Koshkin, A.; Jacobsen, N.; Skouv, J.; Oerum, H.; Jacobsen, M. H.; Wengel, J. *Proc. Natl. Acad. Sci. U.S.A.* **2000**, *97*, 5633–5638. (b) Graziewicz, M. A.; Tarrant, T. K.; Buckley, B.; Roberts, J.; Fulton, L.; Hansen, H.; Ørum, H.; Kole, R.; Sazani, P. *Mol. Ther.* **2008**, *16*, 1316–1322. (c) Straarup, E. M.; Fisker, N.; Hedtjarn, M.;

Lindholm, M. W.; Rosenbohm, C.; Aarup, V.; Hansen, H. F.; Ørum, H.; Hansen, J. B.; Koch, T. *Nucleic Acids Res.* **2010**, *38*, 7100–7111. (d) Lanford, R. E.; Hildebrandt-Eriksen, E. S.; Petri, A.; Persson, R.; Lindow, M.; Munk, M. E.; Kauppinen, S.; Ørum, H. *Science* **2010**, *327*, 198–201. (e) Obad, S.; Dos Santos, C. O.; Petri, A.; Heidenblad, M.; Broom, O.; Ruse, C.; Fu, C.; Lindow, M.; Stenvang, J.; Straarup, E. M.; Hansen, H. F.; Koch, T.; Pappin, D.; Hannon, G. J.; Kauppinen, S. *Nat. Genet.* **2011**, *43*, 371–378.

(14) For an updated clinical status of LNA, see: <http://www.santaris.com/product-pipeline>.

(15) Wienholds, E.; Kloostermann, W. P.; Misk, W. P.; Alvarez-Saavedra, E.; Berezikov, E.; Bruijn, E.; Horvitz, H. R.; Kauppinen, S.; Plasterk, R. H. A. *Nature* **2005**, *309*, 310–311.

(16) For particularly interesting earlier examples see: (a) Sørensen, M. D.; Kværnø, L.; Bryld, T.; Håkansson, A. E.; Verbeure, B.; Gaubert, G.; Herdewijn, P.; Wengel, J. *J. Am. Chem. Soc.* **2002**, *124*, 2164–2176. (b) Sørensen, M. D.; Petersen, M.; Wengel, J. *Chem. Commun.* **2003**, 2130–2131. (c) Morita, K.; Takagi, M.; Hasegawa, C.; Kaneko, M.; Tsutsumi, S.; Sone, J.; Ishikawa, T.; Imanishi, T.; Koizumi, M. *Bioorg. Med. Chem.* **2003**, *11*, 2211–2226. (d) Fluiter, K.; Frieden, M.; Vreijling, J.; Rosenbohm, C.; De Wissel, M. B.; Christensen, S. M.; Koch, T.; Ørum, H.; Baas, F. *ChemBioChem* **2005**, *6*, 1104–1109. (e) Albæk, N.; Petersen, M.; Nielsen, P. *J. Org. Chem.* **2006**, *71*, 7731–7740. (f) Varghese, O. P.; Barman, J.; Pathmasiri, W.; Plashkevych, O.; Honcharenko, D.; Chattopadhyaya, J. *J. Am. Chem. Soc.* **2006**, *128*, 15173–15187. (g) Abdur Rahman, S. M.; Seki, S.; Obika, S.; Yoshikawa, H.; Miyashita, K.; Imanishi, T. *J. Am. Chem. Soc.* **2008**, *130*, 4886–4896. (h) Mitsuoka, Y.; Kodama, T.; Ohnishi, R.; Hari, Y.; Imanishi, T.; Obika, S. *Nucleic Acids Res.* **2009**, *37*, 1225–1238. (i) Zhou, C.; Liu, Y.; Andaloussi, M.; Badgujar, N.; Plashkevych, O.; Chattopadhyaya, J. *J. Org. Chem.* **2009**, *74*, 118–134. (j) Seth, P. P.; Siwkowski, A.; Allerson, C. R.; Vasquez, G.; Lee, S.; Prakash, T. P.; Wancewicz, E. V.; Wittchell, D.; Swayze, E. E. *J. Med. Chem.* **2009**, *52*, 10–13.

(17) For reviews, see: (a) Luyten, I.; Herdewijn, P. *Eur. J. Med. Chem.* **1998**, *33*, 515–576. (b) Ahmadian, M.; Bergstrom, D. E. In *Modified Nucleotides in Biochemistry, Biotechnology and Medicine*, 1st ed.; Herdewijn, P., Ed.; Wiley-VCH: Weinheim, Germany, 2008; pp 251–276.

(18) For particularly interesting examples from the original research literature, see: (a) Wagner, R. W.; Matteucci, M. D.; Lewis, J. G.; Gutierrez, A. J.; Moulds, C.; Froehler, B. C. *Science* **1993**, *260*, 1510–1513. (b) Hashimoto, H.; Nelson, M. G.; Switzer, C. *J. Am. Chem. Soc.* **1993**, *115*, 7128–7134. (c) Sagi, J.; Szemzo, A.; Ebinger, K.; Szabolcs, A.; Sagi, G.; Ruff, E.; Otvos, L. *Tetrahedron Lett.* **1993**, *34*, 2191–2194. (d) Ahmadian, M.; Zhang, P. M.; Bergstrom, D. E. *Nucleic Acids Res.* **1998**, *26*, 3127–3135. (e) Heystek, L. E.; Zhou, H. Q.; Dande, P.; Gold, B. *J. Am. Chem. Soc.* **1998**, *120*, 12165–12166. (f) Kottysch, T.; Ahlborn, C.; Brotzel, F.; Richert, C. *Chem. Eur. J.* **2004**, *10*, 4017–4028. (g) Okamoto, A.; Kanatani, K.; Saito, I. *J. Am. Chem. Soc.* **2004**, *126*, 4820–4827. (h) Booth, J.; Brown, T.; Vadha, S. J.; Lack, O.; Cummins, W. J.; Trent, J. O.; Lane, A. N. *Biochemistry* **2005**, *44*, 4710–4719. (i) Skorobogatyi, M. V.; Malakhov, A. D.; Pchelintseva, A. A.; Turban, A. A.; Bondarev, S. L.; Korshun, V. A. *ChemBioChem* **2006**, *7*, 810–816. (j) Østergaard, M. E.; Guenther, D. C.; Kumar, P.; Baral, B.; Deobald, L.; Paszczyński, A. J.; Sharma, P. K.; Hrdlicka, P. J. *Chem. Commun.* **2010**, 4929–4931.

(19) (a) Barbaric, J.; Wagenknecht, H. A. *Org. Biomol. Chem.* **2006**, *4*, 2088–2090. (b) Kocalka, P.; Andersen, N. K.; Jensen, F.; Nielsen, P. *ChemBioChem* **2007**, *8*, 2106–2116. (c) Nguyen, T. N.; Brewer, A.; Stulz, E. *Angew. Chem., Int. Ed.* **2009**, *48*, 1974–1977. (d) Kaura, M.; Kumar, P.; Hrdlicka, P. J. *Org. Biomol. Chem.* **2012**, *10*, 8575–8578.

(20) Sinkeldam, R. W.; Greco, N. J.; Tor, Y. *Chem. Rev.* **2010**, *110*, 2579–2619.

(21) For a recent example, see: Andersen, N. K.; Anderson, B. A.; Wengel, J.; Hrdlicka, P. J. *J. Org. Chem.* **2013**, *78*, 12690–12702.

(22) Østergaard, M. E.; Kumar, P.; Baral, B.; Raible, D. J.; Kumar, T. S.; Anderson, B. A.; Guenther, D. C.; Deobald, L.; Paszczyński, A. J.; Sharma, P. K.; Hrdlicka, P. J. *ChemBioChem* **2009**, *10*, 2740–2743.

(23) Kumar, P.; Østergaard, M. E.; Hrdlicka, P. J. *Curr. Protocols Nucleic Acid Chem.* **2011**, *44*, 4.43.1–4.43.22.

(24) Terminal alkynes were obtained from commercial vendors, synthesized via EDC-mediated coupling between functionalized carboxylic acids and propargylamine (see Scheme S1, Supporting Information) or prepared according to known literature protocols (see the Experimental Section).

(25) (a) Sonogashira, K.; Tohda, Y.; Hagihara, N. *Tetrahedron Lett.* **1975**, *50*, 4467–4470. (b) Agrofoglio, L. A.; Gillaizeau, I.; Saito, Y. *Chem. Rev.* **2003**, *103*, 1875–1916.

(26) Schrock, A. K.; Schuster, G. B. *J. Am. Chem. Soc.* **1984**, *106*, 5234–5240.

(27) Park, S. Y.; Yoon, J. H.; Hong, C. S.; Souane, R.; Kim, J. S.; Mathews, S. E.; Vicens, J. *J. Org. Chem.* **2008**, *73*, 8212–8218.

(28) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **2002**, *41*, 2596–2599.

(29) Bryld, T.; Lomholt, C. *Nucleosides Nucleotides Nucleic Acids* **2007**, *26*, 1645–1647.

(30) Mergny, J. L.; Lacroix, L. *Oligonucleotides* **2003**, *13*, 515–537.

(31) Gyi, J. I.; Gao, D.; Conn, G. L.; Trent, J. O.; Brown, T.; Lane, A. N. *Nucleic Acids Res.* **2003**, *31*, 2683–2693.

(32) Demidov, V. V.; Frank-Kamenetskii, M. D. *Trends Biochem. Sci.* **2004**, *29*, 62–71.

(33) (a) Korshun, V. A.; Stetsenko, D. A.; Gait, M. J. *J. Chem. Soc., Perkin Trans. 1* **2002**, 1092–1104. (b) Dohno, C.; Saito, I. *ChemBioChem* **2005**, *6*, 1075–1081. (c) Kumar, T. S.; Madsen, A. S.; Østergaard, M. E.; Sau, S. P.; Wengel, J.; Hrdlicka, P. J. *J. Org. Chem.* **2009**, *74*, 1070–1081.

(34) Marin, V.; Hansen, H. F.; Koch, T. R.; Armitage, B. A. *J. Biomol. Struct. Dyn.* **2004**, *21*, 841–850.

(35) (a) Mayer, E.; Valis, L.; Wagner, C.; Rist, M.; Amann, N.; Wagenknecht, H.-A. *ChemBioChem* **2004**, *5*, 865–868. (b) Hwang, G. T.; Seo, Y. J.; Kim, S. J.; Kim, B. H. *Tetrahedron Lett.* **2004**, *45*, 3543–3546.

(36) (a) Dougherty, G.; Pilbrow, J. R. *Int. J. Biochem.* **1984**, *16*, 1179–1192. (b) Manoharan, M.; Tivel, K. L.; Zhao, M.; Nafisi, K.; Netzel, T. L. *J. Phys. Chem.* **1995**, *99*, 17461–17472. (c) Seo, Y. J.; Ryu, J. H.; Kim, B. H. *Org. Lett.* **2005**, *7*, 4931–4933.

(37) Østergaard, M. E.; Kumar, P.; Baral, B.; Guenther, D. C.; Anderson, B. A.; Ytreberg, F. M.; Deobald, L.; Paszczyński, A. J.; Sharma, P. K.; Hrdlicka, P. J. *Chem. Eur. J.* **2011**, *17*, 3157–3165.

(38) Seitz, O.; Schmuck, E. C.; Wennemers, H. Homogeneous DNA Detection. In *Highlights in Bioorganic Chemistry*; Wiley-VCH: Weinheim, Germany, 2004; pp 311–328.

(39) Quantum yields were not determined for Z-modified duplexes. However, direct comparison with Z5d:DNA, which has a relative fluorescence quantum yield of ~16%,^{18j} suggests that Z5:DNA has a quantum yield of 20–30%.

(40) (a) Yamana, K.; Iwase, R.; Furutani, S.; Tsuchida, H.; Zako, H.; Yamaoka, T.; Murakami, A. *Nucleic Acids Res.* **1999**, *27*, 2387–2392.

(b) Yamana, K.; Zako, H.; Asazuma, K.; Iwase, R.; Nakano, H.; Murakami, A. *Angew. Chem., Int. Ed.* **2001**, *40*, 1104–1106. (c) Mahara, A.; Iwase, R.; Sakamoto, T.; Yamana, K.; Yamaoka, T.; Murakami, A. *Angew. Chem., Int. Ed.* **2002**, *41*, 3648–3650. (d) Hrdlicka, P. J.; Babu, B. R.; Sørensen, M. D.; Harrit, N.; Wengel, J. *J. Am. Chem. Soc.* **2005**, *127*, 13293–13299. (e) Astakhova, I. V.; Korshun, V. A.; Wengel, J. *Chem. Eur. J.* **2008**, *14*, 11010–11026. (f) Wang, G.; Bobkov, G. V.; Mikhailov, S. N.; Schepers, G.; van Aerschot, A.; Rozenski, J.; van der Auweraer, M.; Herdewijn, P.; Feyter, S. D. *ChemBioChem* **2009**, *10*, 1175–1185. (g) Østergaard, M. E.; Cheguru, P.; Pappasani, M. R.; Hill, R. A.; Hrdlicka, P. J. *J. Am. Chem. Soc.* **2010**, *132*, 14221–14228. (h) Astakhova, I. V.; Lindegaard, D.; Korshun, V. A.; Wengel, J. *Chem. Commun.* **2010**, 46, 8362–8364. (i) Förster, U.; Lommel, K.; Sauter, D.; Grünwald, C.; Engels, J. W.; Wachtveitl, J. *ChemBioChem* **2010**, *11*, 664–672. (j) Mansawat, W.; Boonlua, C.; Siri Wong, K.; Vilaivan, T. *Tetrahedron* **2012**, *68*, 3988–3995.

(41) Shen, L.; Siwkowski, A.; Wancewicz, E. V.; Lesnik, E.; Butler, M.; Wittchell, D.; Vasquez, G.; Ross, B.; Acevedo, O.; Inamati, G.;

Sasmor, H.; Manoharan, M.; Monia, B. P. *Antisense Nucleic Acid Drug Dev.* **2003**, *13*, 129–142.

(42) Kumar, P.; Baral, B.; Anderson, B. A.; Guenther, D. C.; Østergaard, M. E.; Sharma, P. K.; Hrdlicka, P. J. *J. Org. Chem.* **2014**, DOI: 10.1021/jo5006153.

(43) For structures of alkynes Ae–g, see Scheme S1 (Supporting Information).

(44) Suenaga, M.; Kaneko, Y.; Kadokawa, J.; Nishikawa, T.; Mori, H.; Tabata, M. *Macromol. Biosci.* **2006**, *6*, 1009–1018.

(45) Godeau, G.; Barthélémy, P. *Langmuir* **2009**, *25*, 8447–8450.

(46) Ott, K.; Schmidt, K.; Kircher, B.; Schumacher, P.; Wiglenda, T.; Gust, R. *J. Med. Chem.* **2005**, *48*, 622–629.

(47) Trybulski, E.; Zhang, J.; Kramss, R. H.; Mangano, R. M. *J. Med. Chem.* **1993**, *36*, 3533–3541.

(48) Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. *J. Org. Chem.* **1997**, *62*, 7512–7515.

(49) Qu, J.; Shiotsuki, M.; Sanda, F.; Masuda, T. *Macromol. Chem. Phys.* **2007**, *208*, 823–832.

(50) Wenting, W.; Wanhua, W.; Shaomin, J.; Hunin, G.; Jiazhang, Z. *Eur. J. Inorg. Chem.* **2010**, 4470–4482.

(51) Andronova, V. L.; Skorobogtyi, M. V.; Manasova, E. V.; Berlin, Y. A.; Korshun, V. A.; Galegov, G. A. *Russ. J. Bioorg. Chem.* **2003**, *29*, 262–266.

(52) Initial screening revealed that this activator results in higher stepwise coupling yields than the normal 4,5-dicyanoimidazole activator.